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ABSTRACT 
Purpose: Knowledge-based planning (KBP) leverages plan data from a database of previously 
treated patients to inform the plan design of a new patient. This work investigated bladder and 
rectum dose-volume prediction improvements in a common KBP method using a Pareto plan 
database in VMAT planning for prostate cancer.  
Methods: We formed an anonymized retrospective patient database of 124 VMAT plans for prostate 
cancer treated at our institution. From these patient data, two plan databases were compiled. The 
clinical plan database (CPD) contained planning data from each patient’s clinical plan, which were 
manually optimized by various planners. The multi-criteria optimization database (MCOD) 
contained Pareto plan data from plans created using a standardized MCO protocol. Overlap volume 
histograms, incorporating fractional OAR volumes only within the treatment fields, were computed 
for each patient and used to match new patient anatomy to similar database patients. For each 
database patient, CPD and MCOD KBP predictions were generated for D10, D30, D50, D65, and D80 
of the bladder and rectum in a leave-one-out manner. Prediction achievability was verified through a 
re-planning study on a subset of 31 randomly selected database patients using the lowest KBP 
predictions, regardless of plan database origin, as planning goals.  
Results: MCOD model predictions were significantly lower (p < 0.001) than CPD model predictions 
for all five bladder dose-volumes and rectum D50 (p = 0.004) and D65 (p < 0.001), while CPD model 
predictions for rectum D10 (p = 0.005) and D30 (p < 0.001) were significantly less than MCOD model 
predictions. KBP model predictions were statistically equivalent to re-planned values for all 
predicted dose-volumes, excluding D10 of bladder (p = 0.03) and rectum (p = 0.04). Compared to 
clinical plans, re-plans showed significant average reductions in Dmean for bladder (7.8 Gy; p < 0.001) 
and rectum (9.4 Gy; p < 0.001), while maintaining statistically similar PTV, femoral head, and penile 
bulb dose.  
 xiv 
Conclusion: KBP dose-volume predictions derived from Pareto plans were lower overall than those 
resulting from manually optimized clinical plans. A re-planning study showed the KBP dose-volume 
predictions were achievable and led to significant reductions in bladder and rectum dose.
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CHAPTER 1. INTRODUCTION 
1.1 BACKGROUND 
1.1.1 RADIATION THERAPY TREATMENT DELIVERY AND PLANNING 
Radiation therapy (or radiotherapy) is the use of high-energy radiation, such as x-rays, 
gamma rays, electrons, or protons, to kill or damage cancer cells. Over half of all cancer patients will 
receive some form of radiotherapy during the course of their treatment.1 Currently, there are two 
main approaches to delivering the prescribed radiation dose: external beam radiotherapy (EBRT), 
which involves large source-to-surface distances, or SSDs; and brachytherapy, which utilizes 
radioisotopes to treat internally or with small SSDs. In EBRT, linear accelerators are used to 
generate and direct megavoltage electrons or photons toward the cancer located within the patient.  
Most modern linear accelerators support different options for delivering the prescribed 
radiation dose to the target for a given patient and disease. 3D conformal radiotherapy (3DCRT) 
collimates radiation fields of uniform intensity around lesions to simultaneously dose the target and 
spare surrounding healthy tissues using multi-leaf collimators (MLCs), which are motorized sets of 
thin, tungsten slabs that move in and out of the field to form different shapes.2 3DCRT was the first 
delivery technique based on 3D anatomical information provided by computed tomography (CT) 
scans. Access to 3D information allows more accurate delineations of targets and healthy organs and 
conformal dose distributions compared to previous delivery methods based on 2D radiographic 
projections.  
Alternatively, fixed-field intensity modulated radiotherapy (IMRT) is a delivery technique 
typically combining five to seven fixed radiation fields of spatially varying fluence patterns. Each 
beam’s modulated intensity profiles are achieved by combining complex sequences of MLC leaf 
travel, which are set to optimize the composite dose distribution. IMRT combines the non-uniform 
fluence maps from each beam (aimed from different directions) to create highly conformal dose 
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distributions that improve target coverage and in sparing of normal tissues compared to 3DCRT.3,4 
However, longer treatment delivery times and increased monitor units (MUs) are limitations for 
IMRT treatments. The latter can increase radiation exposure to parts of the body distant from the 
treatment field, whereas the former can impair patient comfort and reproducibility.5 In order to 
overcome these deficiencies, arc-based or rotational treatment techniques were developed, where 
radiation is delivered while rotating the linear accelerator about the target.  
Volumetric modulated arc therapy (VMAT), one such rotational IMRT technique, delivers 
intensity modulated fields by continuously varying three main parameters: rotation speed of the 
linear accelerator gantry, MLC positions, and dose rate (Figure 1).6 VMAT dose is computed by 
approximating a continuous arc with a large number of discrete segments. The non-uniform fluence 
profiles and ensuing MLC sequences are optimized at each control point (each segment lies between 
two control points) to create highly conformal intensity modulated dose distributions. Compared to 
fixed-field IMRT, VMAT requires fewer MUs and provides a significantly shorter treatment time.7 
Due to the relatively recent clinical implementation of VMAT, its overall dosimetric advantages over 
fixed-field IMRT are uncertain. Some studies have reported potential benefits of VMAT for specific 
treatment sites like the prostate, while others have found inconsistent dosimetric results between 
IMRT and VMAT for head-and-neck treatments.7-12 Primarily owing to efficiency, VMAT has 
quickly become a ubiquitous treatment technique for cases requiring intensity modulation. 
Radiotherapy treatment planning is the process of defining how the prescribed dose is to be 
delivered during treatment. More specifically, a treatment plan specifies the machine parameters to 
produce the desired dose distribution for the given patient. These parameters can include the 
number of beams, beam energy, beam shape, beam weight, gantry angle, intensity modulators (e.g. 
wedges, tissue compensators, MLCs), and couch angle. Computerized treatment planning systems 
(TPSs) are used to help determine these parameters to arrive at a customized treatment plan for each 
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patient. Even with the assistance of computers, treatment plan design is time-consuming and highly 
complex given the large number of parameters the must be specified.  
 
Figure 1: Diagram of a modern linear accelerator, highlighting the three varying parameters that 
differentiate VMAT from other EBRT delivery techniques.13,14 
There are two main approaches to treatment planning used today, each of which facilitate 
specific delivery techniques. “Forward planning” is employed to design treatment plans for 
conventional, uniform intensity techniques (e.g. 3DCRT). Forward planning is the process of 
manually adjusting treatment parameters to obtain the desired dose distribution. If a patient is to be 
treated with 3DCRT, for instance, the planners must manually find the appropriate machine and 
treatment parameters to obtain an acceptable plan. This forward planning approach forces planners 
to determine these parameters effectively by trial-and-error, where the dose must be computed and 
evaluated each time a set of parameters is selected. Moreover, if the resulting dose distribution is not 
Varying MLC Positions 
Varying 
Dose 
Rate 
Varying 
Gantry 
Speed 
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acceptable, the parameters are manually adjusted and the dose is recomputed for evaluation. These 
iterations continue until the desired dose distribution is achieved.  
Alternatively, “inverse planning” is used for planning more complex treatment delivery 
techniques such as IMRT and VMAT. These techniques require many intricate MLC sequences for 
each field or arc segment to generate the necessary modulated fluence patterns. Manually optimizing 
these varying fluence maps and corresponding MLC sequences for each beam via forward planning 
would prove prohibitively difficult and laborious.15 Therefore, inverse planning optimization 
algorithms were developed and implemented into TPSs to plan these intensity modulated delivery 
techniques. Inverse planning requires the planner to specify the clinical treatment criteria, after 
which an optimization algorithm automatically determines modulated fluence maps for each beam 
or arc segment that achieve the treatment goals. More specifically, the user defines clinical dose-
volume constraints (i.e. the dose a fractional volume of a planning structure receives) for the target 
and normal tissues, which are represented as cost objective functions for the optimization algorithm 
to minimize. Once the optimizer generates a set of modulated fluence segments and beam 
parameters for the given treatment objectives, the dose is computed and the dose distribution is 
evaluated. If improvement is needed or the planner wants to assess a clinical trade-off, the planner 
must adjust the initial dose-volume objectives and run another optimization. Additionally, clinical 
inverse planning algorithms utilize a gradient-based search for optimal intensity profiles, which 
usually requires multiple optimization rounds to ensure the solution reaches a global, and not a local, 
minimum. This trial-and-error nature of inverse planning resembles that of forward planning, but 
the two protocols differ in the parameters that planners modify after each iteration. Regardless, 
inverse planning can become increasingly time-consuming for complicated cases, like head-and-neck 
patients, that require the assessment of a large number of clinical trade-offs. Paired with the time 
limitations of a clinical environment, this can limit the quality of inverse plans.  
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While it drives the planning of IMRT techniques, inverse optimization reduces a three-
dimensional dose distribution into a set of dose objectives based on one-dimensional dose volume 
histograms (DVHs). This dimensionality reduction in describing dose distributions underscores the 
importance of selecting and adjusting optimal inverse planning objectives. Planners do not currently 
know a priori what the fully optimal treatment plan is for a given patient, let alone the set of planning 
objectives needed to arrive at that plan. Further, clinical dose-volume goals for normal tissues are 
usually derived from population-based clinical studies (e.g. Emami et al.16, Quantitative Analysis of 
Normal Tissue Effects in the Clinic17, Radiation Therapy Oncology Group studies, etc.), which have 
recommended dose tolerances for clinical acceptability but do not provide any patient-specific 
information. This, in addition to unique patient anatomies and the heuristic nature of inverse 
planning, cause the quality of inversely optimized plans to be susceptible to planner bias and 
subjectivity. These limitations of inverse planning have led studies to observe a plan quality 
dependence on planner experience and “skill.”18 Batumalai et al. found within one institution that 
more experienced planners were able to produce superior IMRT plans for a head-and-neck case 
compared with less experienced planners, whose plans were also generally more difficult to deliver 
accurately.19 Planner bias results in plan quality variations between planners and institutions, which 
lead to sub-optimal plans that are clinically-acceptable but more sparing of organs at risk (OARs) is 
possible.20,21 Nelms et al. observed a wide inter-planner variation in plan quality of one prostate 
patient, which they quantified using a “Plan Quality Metric” (PQM) scoring mechanism. The PQM 
algorithm combines 14 target and OAR dose metrics, each assigned a unique value function, to serve 
as treatment goals from a hypothetical physician. With minimum and maximum possible PQM 
values of -10 and 150 respectively, they saw a large range of 58.2-142.5 in PQM (mean of 116.9; 
standard deviation of 16.4) over their 125 plan sample size. This variance in plan quality was 
independent of TPS, delivery modality (IMRT versus rotational), beam angles, total MUs, and 
 6 
planner experience.22 Moore et al. performed a secondary study on the quality of plan data accrued 
for the Radiation Therapy Oncology Group (RTOG) 0126 protocol comparing high dose to 
standard dose 3DCRT/IMRT in patients with localized prostate cancer. They observed 42.9% of 
219 patients with ≥5% excess risk, 9.1% with ≥10% excess risk, and 0.9% with ≥15% excess risk of 
grade ≥2 rectal toxicities. This revealed how sub-optimal inverse planning can leave prostate patients 
vulnerable to excess risk of rectal complications.23  
Inverse planning has been shown to efficiently produce clinically-acceptable plans for 
sophisticated delivery modalities such as VMAT. However, achieving a fully optimal plan via inverse 
optimization requires substantial time and effort to iteratively explore the relevant clinical trade-offs. 
Planners must often sacrifice plan quality for efficiency due to clinical time constraints. The trial-
and-error and heuristic nature of inverse planning can also introduce planner subjectivity and bias, 
further affecting plan quality. Given these inverse planning deficiencies, novel planning methods and 
optimization algorithms aiming to improve patient-specific plan quality and consistency have 
become a focus in medical physics research. 
1.1.2 MULTI-CRITERIA OPTIMIZATION 
One such advanced optimization algorithm aiming to minimize the iterative and subjective 
nature of inverse planning is called multi-criteria optimization (MCO). MCO planning allows for the 
real-time assessment of clinical trade-offs by generating a database of Pareto optimal plans, which 
are plans that are computationally feasible with respect to all constraints and no objective can be 
improved without compromising another. While theoretically there are an infinite number of 
fluence-based Pareto plans, the clinical implementation of MCO used in this study approximates this 
Pareto solution surface through a discrete set of plans that emphasize user-specified planning 
objectives (Figure 2). The first N discrete Pareto plans, where N is the number of specified trade-off 
objectives, are called anchor plans and separately optimize each objective. The N+1th plan, called 
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the “balance plan,” is a Pareto plan that optimizes each trade-off objective with equal weighting. 
Additional auxiliary plans can be generated to better approximate the Pareto surface representation 
if desired.  
 
Figure 2: An example from RaySearch Laboratories of a three-dimensional Pareto surface for a 
prostate plan with three MCO trade-off objectives. The planner can search over this surface in real-
time to consider different clinical trade-offs.24 
 
After a patient-specific database of fluence-based Pareto plans is constructed, the planner 
can dynamically navigate over the computed solution space by adjusting weights assigned to each 
trade-off objective. Then the selected fluence-based Pareto plan is segmented into a deliverable plan 
through direct machine parameter optimization, which minimizes DVH differences between the 
navigated plan and the deliverable plan to optimize MLC segments.25 Then finally, the clinical dose is 
computed.  
Early investigations into the clinical viability of MCO suggest it improves IMRT plan quality 
and efficiency. Craft et al. reported an average IMRT planning time of five glioblastoma and five 
pancreatic cancer patients of 12 minutes using MCO, compared to 135 minutes using traditional 
inverse planning methods. The same study also found physicians blindly identified MCO IMRT 
plans as superior compared to the clinical plan designed through standard inverse optimization.26 
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Kierkels et al. showed novice planners using MCO could create high-quality IMRT head-and-neck 
plans with increased target dose homogeneity and reduced parotid dose compared with conventional 
clinical plans created by experienced planners.27 Similar improvements in planning efficiency and 
quality have been found for MCO VMAT planning.28,29 An example of the potential differences in 
dose distributions between inverse planning and MCO planning is shown in Figure 3. 
  
Figure 3: Example of dose distribution differences between inverse and MCO planning. The same 
axial CT slice of the same prostate patient is shown with the inversely optimized clinical VMAT plan 
on top (a) and a deliverable balance MCO VMAT plan on bottom (b). A noticeable reduction in 
OAR dose is shown in the MCO plan, particularly for both femoral heads. 
 
While MCO is emerging as a viable clinical planning option for reducing inter-planner 
variations in plan quality, its overall dosimetric advantages versus traditional inverse planning remain 
inconclusive. The conversion of a navigated fluence-based dose distribution into a deliverable plan 
(a)
(b)
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can also degrade plan quality.30 However, this effect is correlated with plan complexity and 
investigators have been working on multi-criteria direct-aperture optimization and other methods to 
maximally reduce this conversion error.31-33 MCO’s other limitations are its limited commercial 
availability and substantial computational cost, especially for cases requiring a large amount of trade-
off objectives (e.g. head-and-neck cancer).34,35 
1.1.3 KNOWLEDGE-BASED PLANNING 
An alternative method proposed to reduce inter-planner variations in inversely optimized 
plan quality is knowledge-based planning (KBP). KBP methods have recently been introduced as a 
means of improving plan quality and consistency by leveraging anatomical and dosimetric data from 
previously treated patients to guide the planner in designing a plan for a new patient.  
Knowledge-based concepts have been researched in many aspects of radiation oncology 
such as imaging informatics and segmentation.36-39 However, KBP has become a main area of 
interest due to its potential applications in many aspects of the treatment planning process. For 
instance, KBP models have been used to predict patient-specific dose-volume objectives (based on 
the available previous knowledge) before inverse optimization. Chanyavanich et al. used such an 
approach with an algorithm based on mutual information to retrospectively predict prostate IMRT 
plans that were dosimetrically similar to the original clinical plans.40 KBP models can also serve as 
post-planning quality control tools by flagging patient plans where lower OAR dose is predicted 
based on previous patient data. Wu et al. developed a quality control model to flag parotids planned 
with too high a dose in IMRT head-and-neck cases.41 Also, KBP methods have been used in 
exploring the feasibility of automated planning systems that require no human intervention. Tol et al. 
recently assessed the ability of RapidPlan, Varian’s commercial knowledge-based planning module, 
to automate plan quality assurance for clinical trials.42 The possibility of achieving fully automated 
clinical treatment planning within the next ten years was recently debated.43 If this goal is to be 
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realized at any point in the future, let alone in ten years, KBP research may be important in its 
development and implementation. 
In a general KBP dose prediction model, a database of previously treated patients with high-
quality treatment plans is established. Then for a new patient (to be planned), the database is 
searched for a subset of prior patients with similar anatomy to the new patient. The dose data from 
those anatomically similar database patients are then used to predict dose-volume objectives for the 
new patient’s plan. This KBP method provides empirical dose predictions based on the patient’s 
unique anatomy. This kind of patient-specific a priori information is not present in the current 
clinical planning paradigm, where population-based dose tolerances for OARs are typically applied 
as planning constraints. Moreover, a KBP model can explicitly predict personalized DVH objectives 
or dose-volumes for new patients using previous patient data.  
Several approaches to KBP have been described in the literature. Appenzoller et al. proposed 
a KBP method using mathematical models to predict achievable OAR DVHs based on patient 
anatomy to reduce IMRT planning variability and improve treatment plan quality.44 They separated 
each OAR into sub-volumes based on the distance a collective group of voxels was away from the 
planning target volume (PTV) surface. Then all sub-DVHs (DVHs of the individual sub-volumes) 
were fitted to skew-normal distributions, which were used to predict DVHs. This predictive DVH 
model has been successfully used in quality control studies for IMRT planning.23,45 Shiraishi et al. 
further adapted this methodology to predict DVHs and identify sub-optimal plans for stereotactic 
radiosurgery (SRS) cases.46 Good et al. developed a KBP model to predict dose for 7-field IMRT 
prostate plans based on the mutual information between the beam’s-eye-view projections of a new 
patient and database patients. They found the KBP plans to have superior (i.e. lower) bladder and 
rectum DVHs compared to original clinical plan in 40% of cases.47 Moore et al. observed increased 
normal tissue sparing and reduced inter-planner variability in IMRT prostate and head-and-neck 
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cases after implementing a KBP model that correlated OAR volume overlapping the PTV with 
mean OAR dose.48 Principal component analysis (PCA) based KBP models have also been used to 
investigate how anatomical and dosimetric features affect OAR dose in prostate and head-and-neck 
patients for DVH prediction purposes.49-52 Varian’s commercial KBP optimization engine RapidPlan 
(Varian Medical Systems, Palo Alto, CA, USA) uses a combination of PCA and regression models to 
estimate DVH predictions.53 Nwankwo et al. developed an algorithm that predicted dose to each 
OAR voxel in VMAT plans of prostate patients by learning OAR sparing patterns from a database 
of previous clinical plans.54 Similarly, Shiraishi et al. used previously treated VMAT prostate and SRS 
head-and-neck plans to train an artificial neural network to predict patient-specific dose matrices for 
new cases.55 Each of these studies aims to simultaneously improve plan quality and reduce plan 
variability regardless of changing patient and planning variables. 
1.1.4 THE OVERLAP VOLUME HISTOGRAM IN KBP 
The quality of a treatment plan depends primarily on patient anatomy, particularly the 
geometrical relationship between PTVs and OARs. Using mathematical phantoms, Hunt et al. 
showed that PTV uniformity and maximum OAR dose depend strongly on PTV-OAR geometry, 
specifically the distances between them.56 They also performed a separate study that showed a 
correlation between the OAR volume overlapping the PTV and OAR sparing in head-and-neck 
cases.57 Similarly, studies on examining prostate cancer have shown an increase in rectum and 
bladder dose as prostate and seminal vesicle volumes increase.58 
The investigations on anatomical influence on dosimetric outcomes have led to several novel 
metrics relating patient anatomy to dose prediction. One common metric used in KBP DVH 
prediction models to correlate patient geometry to OAR dose is called the overlap volume histogram 
(OVH). Introduced by Kazhdan et al., the OVH is a shape relationship descriptor that quantifies a 
patient’s anatomy by defining the distance a fractional OAR volume lies from the PTV surface. 
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More specifically, it is defined for a target T and organ O, where the value of the OVH of O with 
respect to T at distance r is defined as the fractional organ volume a distance of r or less from the 
target: 
 𝑂𝑉𝐻$,& 𝑟 = )∈$|,(),&)/0$ , (1.1) 
where d(p,T) is the signed distance of a point p from the target’s boundary and |O| is the volume of 
the OAR.59  
The clinical viability of OVH-driven quality control tools and KBP methods have been 
investigated due to the metric’s robustness and ease of clinical implementation. Wu et al. used the 
OVH within a KBP method as an anatomical similarity metric for matching a new patient to 
previous IMRT head-and-neck patients in a database. Their OVH-driven KBP model predicted 
DVH objectives for the new patients, which led to significant decreases in planning time and dose to 
the spinal cord, brainstem, and contralateral parotid.60 They have also shown the effectiveness of 
KBP methods utilizing the OVH in improving the quality, efficiency, and consistency of 
simultaneous integrated boosted-IMRT and VMAT planning for head-and-neck cancer.61,62 Further, 
they have adapted their OVH-driven KBP methodology for robotic stereotactic body radiotherapy 
(SBRT) and were able to improve bladder and rectum sparing in prostate cases.63 Likewise, Zhu et al. 
introduced the distance-to-target histogram (DTH) as a metric to estimate OAR DVHs to improve 
IMRT plan quality.49 The DTH is virtually identical to the OVH, but Zhu et al. differentiate their 
DTH by incorporating non-Euclidean distance metrics.64  
All OVH-driven KBP methods assume that the dose received by a fractional OAR volume 
depends on its proximity to the PTV, which is described quantitatively by the OVH. Therefore, each 
point on an OAR’s OVH can be mapped to one point on the corresponding DVH, establishing a 
one-to-one relationship for each OAR of each database patient. This one-to-one distance-to-dose 
mapping can be formed by relating a distance rv of an OVH for a fractional OAR volume v to a 
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dose-volume Dv of a DVH (Figure 4). This serves as the foundation of using the OVH as an 
anatomical similarity metric in a KBP model for predicting DVH dose-volumes. Further, the simple 
yet powerful nature of the OVH makes it a desirable metric to relate patient anatomical features to 
optimally achievable dose distributions in KBP methods. 
 
Figure 4: Illustration from Wu et al. relating the distance a fractional OAR volume (v) lies from the 
PTV surface (rv) on the OVH (left) to the dose the fractional volume receives (Dv) on the DVH 
(right).63 
1.2 MOTIVATION FOR RESEARCH 
Many of the previous studies have concluded that the performance or accuracy of a 
particular KBP model depends directly on the quality of the plans in the patient database.60,65-69 
These original database plans in a majority of KBP studies were created via inverse planning, which 
means the KBP models are still subject to the same deficiencies of inverse planning. Recognizing 
this, Schmidt et al. utilized dose warping and scaling reduce the impact of sub-optimal inverse plans 
on the performance on their mutual information-based KBP model.66 Sub-optimal clinical plans are 
difficult to detect due to the substantial time and labor involved in fully assessing clinical trade-offs 
through the trial-and-error process of inverse optimization. Plan quality fluctuations can also result 
from varying planning priorities from patient-to-patient and planner-to-planner (or physician-to-
physician). In fact, Wang et al. recently used an in-house TPS to evaluate the performance of an 
OVH-driven KBP method based on Pareto optimal treatment plans for prostate cases, independent 
of these non-uniform treatment planning priorities.69 They found the OVH model was highly 
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accurate in predicting rectum and anus dose, but systematically underestimated achievable bladder 
dose likely due to the bladder’s lower planning priority relative to the rectum. However, the potential 
improvements in OVH-driven KBP performance utilizing a plan database with uniform planning 
priorities and void of sub-optimal inverse plans have not been examined to our knowledge. 
KBP’s susceptibility to planner bias and plan variations can be avoided through the use of 
MCO at the cost of computational burden. Therefore, the purpose of this study was to investigate 
the performance of a MCO-driven KBP planning approach as an efficient solution. Specifically, this 
work examined OVH-driven KBP dose-volume prediction dependence on database plan quality for 
VMAT treatment planning of the prostate. The study compared the use of a database containing 
manual, inversely optimized clinical plans (referred to as the CPD – clinical plan database) against a 
database of plans generated with MCO (referred to as the MCOD). Two sets of OVH-driven KBP 
dose-volume predictions for the bladder and rectum were generated: one set derived from the 
original clinical plan data (CPD) and the other set derived from the Pareto optimal plan data 
(MCOD). The optimality of the two sets of predictions were compared and their achievability was 
verified through a re-planning study. 
1.3 HYPOTHESIS AND SPECIFIC AIMS 
The hypothesis of this work was that OVH-driven KBP predictions using a MCO plan 
database (MCOD) will lead to plans with statistically significant improvements (p < 0.017) in bladder 
and rectum dose while maintaining statistically equivalent or superior target and secondary OAR 
(femoral heads and penile bulb) dose, compared with using a clinical plan database (CPD). In order 
to test this hypothesis, three specific aims were developed for this study: 
Aim 1: Establish a retrospective anonymous patient database; compile the OVH, CPD, and 
MCOD knowledge databases; investigate second-order factors influencing the 
distance-to-dose correlation strength while accounting for inter-planner variability. 
 15 
Aim 2: Develop and apply OVH-driven KBP model for predicting bladder and rectum 
dose-volumes using each plan database; statistically analyze any dosimetric 
differences between CPD and MCOD KBP model predictions. 
Aim 3: Perform a re-planning study by applying KBP dose-volume predictions as planning 
goals; statistically analyze differences between re-planned and predicted KBP model 
values to verify the achievability of KBP model predictions. 
1.4 OVERVIEW OF THESIS 
This document follows a manuscript-style thesis format. The introductory Chapter 1 
contains background information for the entire study and establishes the motivation and central 
themes of this research. Chapter 2 and Chapter 3 mirror two separate manuscripts respectively 
prepared for submission to peer-reviewed scientific journals, of which the former has been 
submitted for peer-review at the time of writing this thesis. These two chapters contain their own 
materials and methods, results, discussion, and conclusions sections. Background and introductory 
information for both manuscript chapters were consolidated into Chapter 1 to avoid redundancies. 
Chapter 4 summarizes the overall findings of the study and discusses limitations and directions for 
future work. This thesis contains only one References section (again to avoid redundancies) and 
each cited work is listed in the order in which they appear in the document. Lastly, the Appendix 
contains extraneous methods and supplementary data either not mentioned or implicitly mentioned 
in the materials and methods sections of the thesis. 
Generally, the specific aims laid out in Chapter 1.3 are addressed chronologically in this 
thesis. In other words, if aligning the specific aims to specific chapters, Aim 1 is contained in 
Chapter 2 while Aims 2 and 3 are contained in Chapter 3. However, certain aspects of the specific 
aims are inherently present in both manuscript chapters. 
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CHAPTER 2. AN IMPROVED DISTANCE-TO-DOSE CORRELATION 
FOR PREDICTING BLADDER AND RECTUM DOSE-VOLUMES IN 
KNOWLEDGE-BASED VMAT PLANNING FOR PROSTATE CANCER 
2.1 MATERIALS AND METHODS 
2.1.1 PATIENT DATABASE 
We developed a database, compliant with the Health Insurance Portability and 
Accountability Act (HIPAA), of 124 prostate cancer patients previously treated at Mary Bird Perkins 
Cancer Center. Selected patients were prescribed dose to a single PTV and treated using two 
coplanar, 6 MV VMAT beam arcs. Patients with artificial hip prostheses, where beams are 
prohibited from entering through the implant, and patients with sequential boosts were excluded. 
Selected patients included those having post-operative prostate fossa, seminal vesicle involvement, 
and pelvic lymph node involvement where only a single PTV was irradiated. A statistical summary of 
the resulting patient database is shown in Table 1.  
All patients in the database had an existing treatment plan that had been manually optimized 
by different planners using the commercial TPS currently used clinically at our institution (Pinnacle3, 
v9.8, Philips Medical Systems, Hanover, WI, USA). For the purpose of the present study, it was 
desirable to reduce planner-to-planner variability. Accordingly, all database patients were re-planned 
with a different commercial TPS with available tools for minimizing inter-planner variability 
(RayStation, v4.5.1.14, RaySearch Laboratories, Stockholm, Sweden). 
Specifically, re-plans were objectively generated for each database patient using MCO. As 
mentioned previously, MCO is a novel optimization algorithm based on a combination of Pareto 
optimal plans generated from user-specified trade-off objectives and constraints. Pareto optimal 
plans are those where the constraints are computationally feasible and no objective can be improved 
without worsening another. In the TPS, a “balanced plan” is the Pareto plan giving equal weight to 
all objectives.24 Previous studies have indicated MCO can provide superior plan quality and planning 
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Table 1: Distribution of patient characteristics in the database. The selected patients cover a wide 
range of prescription doses, treatment areas, and target volumes. SV stands for seminal vesicle 
involvement and LN stands for lymph node involvement. 
Prescription 
Dose Range (cGy) Number of Patients 
4500 - 7000 38 
7000 - 7600 43 
7600 - 8100 33 
8100 10 
Treatment Area  
Prostate Only 66 
Prostate Fossa 23 
Prostate + SV 
Or 
Prostate + SV + LN 
35 
PTV Volume 
Range (cm3)  
69 - 150 22 
150 - 225 56 
225 - 300 19 
300 - 729 27 
efficiency compared to traditional inverse planning.26,29 Therefore, the MCO balance plan for each 
patient was used to maximize both plan consistency and quality. Each MCO plan was created to 
match the previous prescription dose using a standard set of trade-off objectives and constraints, 
which produced consistent Pareto optimal dose distributions (Table 2). In order to account for 
patients with different prescription doses, the dose for each patient was normalized such that 95% 
of the PTV received 7600 cGy. It is important to note the effects of this scaling were examined and 
found to have no measurable impact on the dose distributions, allowing for inter-plan comparisons.  
The scripting feature in RayStation was leveraged to automate the computation of bladder 
and rectum OVHs for each database patient by uniformly contracting or expanding the PTV in 1 
mm step sizes. This OVH data was used to describe the PTV-OAR geometrical information of the 
database patients. 
To determine the strength of the distance-to-dose relationship for 30, 50, 65, and 80% 
bladder and rectum dose-volumes of database patients, the correlations between database OVHs 
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and DVHs for those specific bladder or rectum dose-volumes were calculated using the Pearson 
product-moment correlation coefficient (R). 
Table 2: MCO planning objectives and constraints used in generating balance plans for each 
database patient. The Dose Fall-off objective for the External structure reduces dose outside of the 
target. Rx refers to the prescription dose. 
Structure Trade-off Objectives (cGy) 
Constraints 
(cGy) 
PTV Uniform Dose = Rx Min Dose = Rx Max Dose = Rx + 100 
Bladder Max EUD = 0, (a=2)  
Rectum Max EUD = 0, (a=2)  
Left and Right 
Femoral Heads Max EUD = 0, (a=2)  
Penile Bulb Max EUD = 0, (a=2)  
External Dose Fall-off = [H] 3000 [L] 0,  Low Dose Distance = 5 cm  
2.1.2 SECOND-ORDER FACTORS 
An array of dosimetric and anatomical second-order factors were chosen to examine for 
correlation with OAR dose. These factors included the derivative of the OVH (dOVH), prescription 
dose, PTV volume, bladder volume, rectum volume, and in-field OAR volume. The dOVH 
quantifies the specific orientation of the OAR relative to the PTV, where a higher dOVH value 
describes an OAR likely more difficult to spare than one with a lower dOVH. For example, it is 
possible for equal fractional OAR volumes in two different patients to have similar OVH distances, 
but have differing dOVH values that could lead to a difference in the dose each volume receives. In-
field OAR volume was defined as the amount of OAR volume that lies within transverse planes 
located 6 mm (approximating the beam penumbra at depth) superior and inferior to the most 
superior and inferior aspects of the PTV respectively.  
The ability of each second-order term to strengthen distance-to-dose correlations was 
quantified by computing the Pearson product-moment correlation coefficient (R). This coefficient 
was calculated for each factor and OAR dose-volume pair over each of the four fractional bladder 
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and rectum volumes previously listed in Chapter 2.1.1. The resulting correlation coefficients were 
averaged over the four fractional volumes for each OAR. The second-order factor with the 
strongest mean correlation with OAR dose was determined to be the strongest contributor to the 
DVH-OVH correlation variation for the given OAR. 
2.1.3 IMPROVED DISTANCE-TO-DOSE CORRELATION 
After the factor with the strongest effect on the distance-to-dose correlation variation was 
determined for the bladder and rectum, the DVH-OVH correlations were recomputed while 
including the second-order factor. These improved (OVH plus second-order term) correlations were 
compared to the nominal (OVH only) correlations to quantify any improvements in the database 
distance-to-dose correlations.  
As will be shown in the Results section, the in-field OAR volume was found to be the 
strongest contributor to variations in correlation between distance and dose for both the bladder 
and the rectum. As such, the OVH was also recomputed by disregarding out-of-field volume. 
Described by Petit et al., the in-field OVH is calculated similarly to the total OVH except only the in-
field OAR volume is considered when determining the overlapping OAR volume with the 
contracted or expanded target volume.65 This introduces a slight modification to Equation (1.1): 
 𝑂𝑉𝐻$,& 𝑟 = 𝑝 ∈ 𝑂2|𝑑(𝑝, 𝑇) ≤ 𝑟𝑂  (2.1) 
 
where O’ is the portion of the organ O within the treatment fields (defined previously). The 
computational endpoint for the in-field OVH of a given OAR is when the PTV is expanded to 
overlap the entire in-field portion of the OAR’s volume. Further, the in-field OVH distance for 
100% overlap volume exists only when the entire OAR is within the defined treatment fields. 
Therefore, those patients in the database with fractional in-field OAR volumes less than the selected 
dose-volume value will not contribute to forming the dose-to-distance correlation. For example, if 
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only 67% of the bladder is within the treatment fields for a particular database patient, then that 
patient will not be included when calculating the correlation between the 80% dose-volume and the 
in-field OVH.  
2.2 RESULTS 
2.2.1 NOMINAL DVH-OVH CORRELATION 
Using the nominal OVH to quantify anatomy, the DVH-OVH correlation showed a 
negatively linear relationship in both OARs for each fractional volume observed. Bladder dose 
showed a strong anticorrelation with distance, having a mean R = -0.79 over the four fractional 
volumes analyzed. Rectum dose also showed a strong anticorrelation with distance, having a mean  
R = -0.82 (Table 3). Figure 5 shows each nominal DVH-OVH scatter plot associated with each 
Pearson correlation coefficient listed in Table 3. 
Table 3: Pearson correlation coefficients between nominal OVH distances and DVH dose-volumes 
of the bladder and rectum. An absolute value greater than 0.7 indicates a strong linear correlation 
with a maximum value of 1. 
Dose-Volume DVH-OVH R 
Bladder  
D30 -0.92 
D50 -0.83 
D65 -0.74 
D80 -0.66 
Mean -0.79 
Rectum  
D30 -0.94 
D50 -0.86 
D65 -0.78 
D80 -0.70 
Mean -0.82 
The variation in distance-to-dose correlation across patients can be seen in Figure 5. For 
example, the reader is directed to the DVH-OVH plot for 65% of the rectum (Figure 5 (f)), where 
the range of D65 for an OVH distance of 2 cm was 643 to 3011 cGy. This spread in dose of greater 
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than 2300 cGy for a given OVH distance is consistent with previous studies and illustrates the 
motivation of the present study.52,63,70  
 
Figure 5: Nominal DVH-OVH correlations for 30, 50, 65, and 80% dose-volumes of the bladder (a, 
c, e, g) and rectum (b, d, f, h).  
(a) (b) 
(c) (d) 
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(Figure 5 continued) 
 
 
2.2.2 SECOND-ORDER FACTORS 
Each previously investigated second-order factor was introduced as a variable into the 
nominal DVH-OVH correlation for each fractional volume of the bladder and rectum via a color 
bar. The variables were visually inspected via these color bar scatter plots to assess relational 
dependence between the second-order factors and dose for the fractional OAR volumes. Of all the 
factors studied, only the in-field OAR volume showed any noticeable influence on OAR dose, as 
seen in Figure 6 (c) and (d). The data indicated that, as the in-field OAR volume increases, the dose-
volume value for the associated OAR also increases. This trend was observed in all scatter plots for 
3011 cGy 
643 cGy 
(e) (f) 
(g) (h) 
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every fractional volume DVH-OVH of the bladder and the rectum. For the other factors 
investigated, no such trends were noted (see Figure 6 (a) and (b)). 
 
Figure 6: Sample color scatter plots for qualitative review of dependence on the examined second-
order factors. There is no visible relationship between dose and PTV volume for neither 65% of the 
bladder (a) nor the rectum (b). When analyzing in-field OAR volume however, a clear relationship 
with D65 for the bladder (c) and rectum (d) can be seen. 
Pearson correlation coefficients between second-order factors and bladder and rectum dose-
volumes are listed in Table 4. Of the six variables inspected, only in-field OAR volume showed a 
strong correlation with OAR dose for both the bladder (mean R = 0.86) and the rectum (mean R = 
0.76). The in-field OAR volume had a correlation coefficient of greater than 0.7 for each bladder 
and rectum dose-volume, except for D30 of the rectum. While the dOVH was strongly correlated 
(a) (b) 
(c) (d) 
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with D30 (R = 0.75) and D50 (R = 0.74) of the rectum, the in-field OAR volume resulted in a 
stronger correlation with rectum dose overall. This indicates in-field OAR volume had the strongest 
correlation with OAR dose out of the evaluated factors, confirming the qualitative indications.  
Table 4: Pearson correlation coefficients between each second-order factor and DVH dose-volumes 
for the bladder and rectum. The mean Pearson coefficient over the four fractional volumes is also 
listed. Only the in-field OAR volume was strongly correlated (mean greater than 0.7) for both the 
bladder and rectum. 
Dose-Volume dOVH Rx Dose 
PTV 
Volume 
Bladder 
Volume 
Rectum 
Volume 
In-field OAR 
Volume 
Bladder       
D30 0.62 -0.44 0.50 -0.53 0.20 0.90 
D50 0.56 -0.41 0.41 -0.55 0.19 0.88 
D65 0.52 -0.41 0.39 -0.52 0.17 0.85 
D80 0.48 -0.43 0.38 -0.53 0.18 0.83 
Mean 0.54 -0.42 0.42 -0.53 0.19 0.86 
Rectum       
D30 0.75 -0.60 0.77 0.16 -0.11 0.56 
D50 0.74 -0.49 0.67 0.05 -0.07 0.74 
D65 0.67 -0.43 0.56 -0.07 -0.02 0.87 
D80 0.55 -0.53 0.60 -0.11 -0.09 0.85 
Mean 0.68 -0.51 0.65 < 0.01 -0.05 0.76 
2.2.3 IMPROVED DVH-OVH CORRELATION 
The distance-to-dose correlation showed improvement when the in-field OAR volume was 
accounted for in the computation of the OVH (Table 5). For the bladder, the in-field OVH 
strengthened the mean correlation coefficient from -0.79 to -0.85 over the four fractional volumes. 
While for the rectum, the mean correlation strengthened from -0.82 to -0.86. This increase in 
correlation strength was especially noticeable at the 80% fractional volume level for both the bladder 
and rectum, where the 80% bladder DVH-OVH R strengthened from -0.66 to -0.77 and the value 
for 80% rectum improved from -0.70 to -0.86.  
An illustrative example of the differences between the DVH-OVH correlations using the 
nominal OVH versus the in-field OVH can be seen in Figure 7. Accounting for the in-field OAR 
volume in the OVH computation resulted in an improvement in the distance-to-dose correlation for 
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65% and 80% of the bladder (Figure 7 (a) and (c) respectively) and rectum (Figure 7 (b) and (d) 
respectively). It is important to reiterate that the decrease in data points for the higher fractional in-
field OAR volumes is due to certain database patients not meeting the given in-field OAR volume 
threshold. 
Table 5: Pearson correlation coefficients between in-field OVH distances and DVH dose-volumes 
of the bladder and rectum. The correlation coefficients between the nominal OVH distances and 
DVH dose-volumes from Table 3 are also listed for comparison. Note that n refers to the number 
of database patients with in-field OAR volumes greater than or equal to the given dose-volume. 
 DVH-OVH R 
Dose-Volume Nominal OVH In-field OVH 
Bladder   
D30 -0.92 -0.91 (n = 108) 
D50 -0.83 -0.88 (n = 76) 
D65 -0.74 -0.85 (n = 52) 
D80 -0.66 -0.77 (n = 35) 
Mean -0.79 -0.85 
Rectum   
D30 -0.94 -0.93 (n = 124) 
D50 -0.86 -0.84 (n = 117) 
D65 -0.78 -0.82 (n = 90) 
D80 -0.70 -0.86 (n = 49) 
Mean -0.82 -0.86 
With regards to the representative example of the distance-to-dose correlation variation at 
65% of the rectum introduced earlier (referencing Figure 5 (f)), Figure 7 (b) shows the reduction in 
the dose spread at an OVH distance of 2 cm from using the in-field OVH method. The group of 
patients with rectum D65 less than 10 Gy have very low doses to the rectum, most likely due to 
having less than 65% of the rectum inside the treatment fields. The removal of these patients using 
the in-field OVH term reduces the dose spread at the OVH distance of 2 cm from over 20 Gy with 
the nominal OVH method to less than 10 Gy.  
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Figure 7: Representative examples of improved distance-to-dose correlations using the in-field OVH 
compared with the nominal OVH. The figure legends contain the number of patients (n) and the 
Pearson correlation coefficients (R) for each OVH method. The square nominal OVH data points 
are equivalent to the scatter plots shown in Figure 5. 
2.3 DISCUSSION 
In-field OAR volume was observed to be the largest contributor to variations in the 
distance-to-dose relationship for fractional overlap volumes of bladder and rectum in prostate 
patients treated with VMAT, independent of inter-planner bias. Specifically accounting for OAR 
volume within the treatment fields when computing the OVH strengthened the OVH’s correlation 
with the bladder and rectum dose in these patients. This proposed OVH refinement eliminates data 
points that would likely produce unachievable dose predictions in an OVH-guided KBP tool. This 
(a) (b) 
In-field OVH  
Variation 
Nominal OVH 
Variation 
(c) (d) 
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was evidenced by the consistent removal of a large portion of low-dose data points, which facilitated 
the strengthening of the distance-to-dose correlations. This was seen most clearly for the lower 
dose-volumes of both OARs e.g. D65 and D80 shown in Figure 7. Therefore, determining in-field 
OAR volume as an influencing factor in the DVH-OVH correlation, and accounting for this 
through the in-field OVH, will allow for more achievable and accurate dose predictions for OVH-
guided KBP models.  
Previous studies have refined OVH-guided KBP methods for different treatment sites to 
generate more precise planning predictions without fully quantifying the resulting effects on the 
distance-to-dose correlation used to estimate the DVH objectives. Reddy et al. found prostate 
volume was directly proportional to bladder and rectum dose in 3D-CRT and IMRT plans.58 
Similarly, Wu et al. implemented an empirical PTV volume filter, querying a patient database for a 
subset of patients with specific OVH values and similar PTV volumes for their KBP method for 
localized prostate patients treated with robotic SBRT.63 This work shows PTV volume to be 
moderately correlated with bladder dose (mean R = 0.42) and rectum dose (mean R = 0.65), which 
validates PTV volume as a simple, yet viable second-order factor when predicting bladder and 
rectum dose-volumes for OVH-guided KBP methods for prostate patients. However, our work also 
shows that filtering patients based on in-field bladder and rectum volume and even dOVH would 
provide an even stronger distance-to-dose model compared to using PTV volume, resulting in more 
robust dose-volume predictions. While in-field OAR volume may not be as easily defined for 
robotic SBRT as with VMAT treatments given the multitude of non-coplanar and non-isocentric 
beams, the relationship between OAR dose and in-field volume should hold across different 
treatment techniques. 
This work also confirms and builds upon the findings by Petit et al., who demonstrated that 
utilizing the in-field OVH will result in more accurate and fewer unachievable dose predictions for 
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cases with sizable portions of nearby OARs lying outside the treatment fields.65 While their group 
analyzed the in-field OVH’s effects with pancreatic adenocarcinoma patients treated with IMRT, our 
similar findings with VMAT prostate cases support the in-field OVH’s efficacy in OVH-guided 
KBP methods in any treatment site. A novel component of our study is the reduction of inter-
planner variability through the generation and implementation of a Pareto optimal plan database. 
Even with this decrease in inter-planner subjectivity, the in-field OAR volume was still found to be 
the strongest second-order factor correlating with OAR dose in these standardized plans. Another 
noted difference between these two studies is the definition of in-field volumes. Petit et al. defined a 
1 cm margin around the beams-eye-view of the PTV as the field edges, where we defined our in-
field transverse plans to be 0.6 cm superior and inferior of the most superior and inferior aspects of 
the PTV. Differences in results depending on in-field volume definitions would require further 
analysis. Regardless, our results support the claim that accounting for in-field OAR volume will lead 
to more precise and accurate OVH-driven KBP dose predictions. 
Additionally, this study supplements the results reported by Yuan et al., who analyzed factors 
impacting interpatient OAR dose sparing. While they used a stepwise multiple regression model on 
prostate and head-and-neck IMRT treatments, out-of-field OAR volume (converse to in-field 
volume) was found to be a significant factor in determining OAR dose sparing.52 It should also be 
noted this group utilized a non-Euclidean form of the OVH to account for voxels outside treatment 
fields to form their distance-to-dose correlation, resulting in a reduction in the correlation variation. 
Our work shows a similar reduction in distance-to-dose correlation spread using the in-field OVH. 
This study presents a comprehensive analysis and review of second-order factors potentially 
influencing the distance-to-dose relationship, which serves as the foundation for OVH-driven KBP 
dose prediction methods. As opposed to previous studies using patient cohorts with uniform beam 
configurations, dose prescriptions, and disease types, this work analyzes distance-to-dose correlation 
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behavior in a large patient database with a wide range of treatment parameters and structure volume 
sizes. Another feature unique to this work, that must be reiterated, was the implementation of an 
objective and standardized MCO planning protocol applied to each of the 124 database patients. 
This served to maximally reduce plan quality variations from patient to patient due to the inherent 
subjectivity and inconsistencies from inverse treatment planning and inter-planner variations. The 
composite impact of these factors was inspected over the low-, medium-, and high-dose levels of the 
OAR DVHs, capturing the overall influence each factor has on the distance-to-dose correlation.  
These results indicate an improvement in the distance-to-dose correlation, which can be 
implemented in existing OVH-guided KBP dose prediction tools by recalculating the OVH based 
on in-field OAR volume. While this reduction in the DVH-OVH correlation variation should lead 
directly to more accurate and less unachievable predictions in a prostate KBP protocol, a 
comprehensive retrospective study needs to be performed to confirm this conclusion. However, this 
study was primarily focused on how second-order factors impacted the distance-to-dose relationship 
in prostate patients treated with VMAT. Although knowledge from this and previous studies 
indicate in-field OVH strengthening the DVH-OVH correlation should generalize to other 
treatment sites, site-specific investigations are needed to support implementation of the in-field 
OVH. 
Although the in-field OVH demonstrated a reduction in distance-to-dose correlation spread, 
further study is needed to investigate how accounting for moderately influencing factors (such as the 
dOVH) would affect this spread. Further, these models could be applied in an existing OVH-guided 
KBP dose prediction tool and a study could be performed to quantify and compare the accuracy and 
achievability of the predictions generated from the unadjusted and adjusted distance-to-dose 
correlations.  
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2.4 CONCLUSIONS 
This work shows the use of the OVH in KBP methods can be improved by accounting for 
in-field OAR volume. Planner bias was minimized by objectively generating Pareto optimal VMAT 
plans for each prostate patient in a large, retrospective database. This facilitated the examination of 
non-systematic contributors or second-order factors affecting inter-plan variability. Out of the 
various treatment and patient parameters investigated, in-field OAR volume was found to correlate 
strongest with OAR dose for both the bladder and rectum. Also, the dOVH was found to be the 
next strongest correlating factor with both bladder and rectum doses, while rectum volume 
correlated least with bladder dose and bladder volume correlated least with rectum volume. 
Differences in prescription dose and PTV volume were found to be moderately correlated with 
bladder and rectum doses. The incorporation of the in-field volume into the OVH showed a 
reduction in distance-to-dose correlation variation, which can lead to more precise and achievable 
dose predictions in KBP methods.  
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CHAPTER 3. USING THE BEST KNOWLEDGE: IMPROVED 
KNOWLEDGE-BASED DOSE PREDICTIONS IN VMAT PLANNING 
FOR PROSTATE CANCER BY USING A PARETO PLAN DATABASE 
3.1 MATERIALS AND METHODS 
3.1.1 PATIENT DATABASE 
A HIPAA-compliant database of 124 prostate cancer patients previously treated at our 
institution was created for this study. Selected patients had only one PTV and were treated with two 
coplanar 6 MV VMAT arcs. Patients with artificial hip implants were excluded due to the reduction 
in degrees of freedom of the treatment arc. Additionally, patients with a sequential boost to a sub-
volume of the initial PTV were excluded. However, post-operative prostate fossa patients were 
included, as were patients with seminal vesicle and lymph node involvement so long as only one 
PTV was defined (Table 1). In order to compare patient plans with differing prescription doses, each 
patient’s dose was normalized so that 95% of the PTV received 76 Gy. 
3.1.2 KNOWLEDGE DATABASES 
The DICOM image set, structure, plan and dose files of all 124 selected database patients 
were imported into a research database of a commercial TPS (RayStation v4.5.1.14, RaySearch 
Laboratories, Stockholm, Sweden). Anatomical and dosimetric knowledge databases were then 
compiled.  
The clinical viability of the OVH as a feature metric in KBP methods has been tested due to 
the metric’s robustness and simple clinical implementation.60-63 Early research into the effectiveness 
of the OVH for sites with large OARs extending outside the treatment fields has demonstrated the 
potential advantages of accounting for the out-of-field OAR volumes through the OVH.52,65 This 
can be done through the in-field OVH, which modifies the standard OVH to include the OAR 
volume only within the treatment fields. Compared to the standard OVH, we have observed the in-
field OVH to improve the distance-to-dose correlation for bladder and rectum dose-volumes in 
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VMAT prostate cases independent of planner-bias. Therefore, the in-field OVH metric was used to 
quantify the anatomical information of each database patient. 
A custom script supported by the TPS (IronPython, Apache) was written to calculate the in-
field OVH for each patient’s bladder and rectum. The in-field OVH was computed by expanding 
and contracting the PTV in 1 mm increments until there was either complete overlap or no overlap 
with the in-field portion of the given OAR. In this study, “in-field” was defined as the volume 
extending laterally to the external patient surface and longitudinally between planes located 6 mm 
superior and 6 mm inferior to the edges of the PTV. The value of 6 mm was chosen to approximate 
the penumbra of the treatment fields.  
To establish the clinical plan database (CPD), a separate script was developed to extract the 
dose volume histogram (DVH) data from each patient clinical treatment plan. The DVHs of the 
PTV, bladder, rectum, femoral heads, and penile bulb (if segmented) for each patient were extracted 
from the TPS and placed in a repository which, along with the anatomic information, formed the 
CPD. Here, the bladder and rectum will be referred to as the primary OARs and the femoral heads 
and penile bulb as secondary OARs. 
For the creation of the MCO database (MCOD), each database patient was re-planned using 
MCO functionality available within the TPS and using the original DICOM image and structure sets 
of the patient. In the TPS, a Pareto plan is generated for each of the user-defined objectives, with 
each plan fully optimized for that specific objective. An additional Pareto plan, called the “balance 
plan,” is created with each of the trade-off objectives weighted equally. The user is then able to 
dynamically navigate over a linear combination of these plans (i.e. the Pareto surface) to assess 
different clinical trade-offs in search of a desired solution for the specific patient. In this study, each 
MCO plan was optimized with a standard set of prescription-specific trade-off objectives and 
constraints (Table 2). After the generation of the Pareto plan databases were completed for each 
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patient, a script was written to extract DVHs from each patient’s balance plan. These dose data were 
placed into a different repository which, along with the same anatomic information used with the 
CPD, formed the MCOD.  
3.1.3 KBP PREDICTIONS AND ANALYSIS 
A KBP method of predicting dose-volumes for the rectum and bladder using the in-field 
OVH was developed for this study. The process generally follows the methodology described by Wu 
et al. and is briefly described here.60  
The fundamental assumption of the approach is that the dose received by a fractional OAR 
volume depends on its proximity to the PTV, which is described quantitatively by the in-field OVH. 
Therefore, each point on an OAR’s in-field OVH can be mapped to one point on the corresponding 
DVH, establishing a one-to-one relationship for each OAR of each database patient. This in-field 
OVH to DVH mapping, in turn, allows the DVH of a new patient to be predicted from database 
patients queried to have similar OAR-PTV anatomy (i.e. in-field OVH values). 
Mathematically, given a new patient n with an in-field OVH distance of rv,n for a specified 
fractional OAR volume of v, the dose that fractional volume receives (Dv,n) can be estimated from a 
knowledge database of i patients by: 
 D7,8 = min D7,< r7,< ≤ r7,8  (3.1) 
The subset of database patients where 𝑟>,? ≤ 𝑟>,@ represents cases where the in-field OVH values 
imply the fractional OAR volumes are at least as difficult to spare as the new patient’s geometry. 
Dose-volumes were predicted for D10, D30, D50, D65, and D80 fractional volumes of bladder 
and rectum. The dose-volume predictions were generated using a leave-one-out method, whereby 
each patient was removed from the database and assumed to be the “new” patient for whom dose-
volumes would be predicted with the 123 database patients that remained.71 This process was 
repeated until predictions were made for each database patient. Two sets of dose-volume predictions 
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were made for each database patient: one set using the CPD model and the other set using the 
MCOD model. For the case where rv,n was less than rv,i for all i database patients, no dose prediction 
was made. In this case, the newly introduced patient would have a fractional OAR volume closer to 
the PTV than any patient in the database. So an achievable dose-volume prediction cannot be 
accurately generated with the given knowledge. Also, given the nature of the in-field OVH, 
predictions were not possible for patients with fractional in-field OAR volumes less than the desired 
dose-volume prediction. For example, a prediction for a patient’s bladder D50 would not be possible 
if less than 50% of that patient’s bladder was within the treatment fields. 
For each of the five dose-volumes of both OARs, three distributions of dose-volumes were 
compared: the set of original clinical values, the set of CPD KBP model predictions, and the set of 
MCOD KBP model predictions. Differences between the three data sets were tested for statistical 
significance using two-sided Wilcoxon signed-rank tests for each dose-volume. Statistical 
significance was set at p = 0.017, which results from applying a Bonferroni correction of three to the 
traditional significance level of 0.05. 
3.1.4 PREDICTION PERFORMANCE AND ACHIEVABILITY 
In order to confirm the achievability of KBP-predicted dose-volumes, 31 patients were 
randomly selected from the original database and re-planned using inverse optimization with the 
bladder and rectum KBP predictions as planning objectives. Because each patient had two sets of 
KBP dose-volume predictions, the lowest dose-volume prediction between the CPD and MCOD 
KBP models was used as the planning goal for each “new” patient. Again, bladder and rectum D10, 
D30, D50, D65, and D80 dose-volumes were used for these re-planning goals. 
Re-plans attempted to maintain similar PTV and secondary OAR dose compared the original 
clinical plans while simultaneously aiming to attain the bladder and rectum KBP dose-volume 
predictions. This was done in order to make an assessment of the clinical achievability of the 
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predicted bladder and rectum KBP dose-volumes. Two-sided Wilcoxon signed-rank tests between 
the bladder and rectum KBP dose-volume predictions and the re-planned values were used to 
quantify prediction achievability. Two-sided Wilcoxon signed-rank tests were also used to verify the 
re-plans maintained clinical PTV and secondary OAR dose. The significance level for these statistical 
tests was set at p = 0.05. Various dose metrics were analyzed to compare PTV and secondary OAR 
dose shown in Table 6. In this study, the homogeneity index (HI) and conformity index (CI) were 
calculated according to their ICRU definitions:72,73 
 HI = DC − DEFDGH  
 
(3.2) 
 CI = treated	volumetarget	volume  (3.3) 
where the treated volume is defined in this study as the tissue volume that receives at least 95% of 
the prescription dose. 
Table 6: Dose metrics used to statistically verify clinical PTV and secondary OAR dose was 
maintained in the re-plans. Vx represents the percent volume receiving x% of the prescription dose. 
Planning Structure Evaluated Dose Metrics 
PTV D2, D50, D98, Dmax, Dmean, Dmin, V95, V98, V100, V107, HI, CI 
Femoral Heads D2, Dmax, Dmean 
Penile Bulb Dmean 
3.2 RESULTS 
3.2.1 DATABASE AND PREDICTION ANALYSIS 
When comparing the DVHs from the two KBP plan databases, the MCOD showed better 
PTV coverage, primary OAR sparing and secondary OAR sparing (Figure 8). On average over the 
124 database patients, the MCOD plans improved PTV HI (p < 0.001) and CI (p < 0.001) compared 
to the CPD plans. The MCOD plans yielded average decreases in Dmean of 21.9 Gy over both 
femoral heads (p < 0.001) and 9.9 Gy for the penile bulb (p < 0.001) compared to the CPD plans. 
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The MCOD plans also decreased the average Dmean of the bladder and rectum by 5.8 (p < 0.001) and 
4.3 Gy (p < 0.001) respectively from the original clinical plans. 
 
Figure 8: Comparison between the average DVHs of the labeled planning structures from plans in 
the CPD (solid lines) and MCOD (dashed lines). Note: the femoral heads are plotted separately (i.e. 
left and right femoral heads) but are difficult to resolve as they are nearly identical and their curves 
overlap each other. 
Figure 9 shows boxplots of differences in bladder and rectum dose-volumes from the 
original clinical plans, the CPD KBP model predictions, and MCOD KBP model predictions. These 
boxplots show how both KBP models compare with the original clinical values including how the 
two KBP models compare with each other. When interpreting the plots in Figure 9, a positive value 
for either of the first two boxes indicates the KBP model prediction was lower than the 
corresponding clinical dose-volume. Additionally, positive values for the third box indicate the 
MCOD model prediction was lower than the corresponding CPD model prediction. 
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Both KBP models generated predictions with a lower median dose than the clinical plans for 
all five bladder and all five rectum dose-volumes. The medians of the MCOD KBP dose predictions 
were lower for all five bladder and three rectum dose-volume points compared to the corresponding 
CPD KBP medians.  
The results from the statistical analysis comparing the patient database dose-volumes from 
the clinical plans, CPD KBP model, and MCOD KBP model are shown in Table 7. For each of the 
five bladder and five rectum dose-volumes analyzed, both the CPD and MCOD KBP model 
predicted statistically lower dose compared to the clinical plans (p < 0.001). 
 
Figure 9: Set of boxplots showing differences in dose-volumes between the clinical plan values, the 
CPD KBP model predictions, and MCOD KBP model predictions for the bladder (a) and the 
rectum (b). Below each dose-volume lists the number of patients, n, where a KBP prediction was 
possible under the protocol detailed in Chapter 3.1.3. Note: data points outside boxplot whiskers are 
more than 1.5 times the interquartile range (first quartile to third quartile i.e. length of boxes) from 
the first or third quartiles, the grey circles represent the mean of each distribution, and the horizontal 
black lines within each box represent the median of each distribution. 
  
(a) 
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(Figure 9 continued) 
 
Bladder dose-volumes predicted from the CPD and MCOD models were on average 7.34 and 11.09 
Gy lower than the clinical values respectively. As for the rectum, the predicted dose-volumes from 
the CPD and MCOD models were on average 8.96 and 8.91 Gy less than the clinical plans 
respectively.  
When comparing the two KBP methods, the MCOD model predicted significantly lower 
dose than the CPD model for all five bladder (p < 0.001) and two of the five rectum dose-volumes 
(D50; p = 0.004 and D65; p < 0.001). The MCOD model bladder dose predictions were on average 
3.75 Gy less than the CPD model predictions over the five dose-volumes. Whereas the MCOD 
model predictions were on average 1.04 Gy less than the CPD model values of D50 and D65 for the 
rectum. CPD model predictions of rectum D10 (p = 0.005) and D30 (p < 0.001) doses were 
(b) 
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statistically lower than the MCOD model. These predicted dose-volumes were on average 1.19 Gy 
lower for the CPD model compared to the MCOD model. 
Table 7: Statistical comparison of CPD and MCOD KBP model and clinical dose-volumes, with 
associated mean differences between combinations of the clinical, CPD model, and MCOD model 
dose values. These mean differences correspond to the grey circles in Figure 9. 
  Mean Differences (cGy) Two-sided Wilcoxon p-values   
Dose 
Metric N
† 
Clinical 
– 
CPD 
Clinical 
– 
MCOD 
CPD 
– 
MCOD 
Clinical 
vs. 
CPD 
Clinical 
vs. 
MCOD 
CPD 
vs. 
MCOD 
Bladder        
D10 123 105.4 677.2 571.8 < 0.001* < 0.001* < 0.001* 
D30 107 598.8 1199.8 600.9 < 0.001* < 0.001* < 0.001* 
D50 75 840.2 1143.4 303.2 < 0.001* < 0.001* < 0.001* 
D65 51 1043.8 1189.6 145.7 < 0.001* < 0.001* < 0.001* 
D80 34 1080.4 1335.7 255.3 < 0.001* < 0.001* < 0.001* 
Rectum        
D10 123 302.4 204.0 -98.4 < 0.001* < 0.001* 0.005* 
D30 123 966.5 827.7 -138.8 < 0.001* < 0.001* < 0.001* 
D50 116 1211.5 1262.5 51.0 < 0.001* < 0.001* 0.004* 
D65 89 1036.3 1192.3 156.0 < 0.001* < 0.001* < 0.001* 
D80 48 961.1 969.0 7.8 < 0.001* < 0.001* 0.049 
*Indicates a statistically significant result of p < 0.017, which was Bonferroni corrected from 0.05 
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible 
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dose-
volume 
3.2.2 KBP PREDICTION ACHIEVABILITY 
Figure 10 shows the average PTV and secondary OAR DVHs from the 31 re-plans 
compared with the corresponding DVHs from the clinical plans. Re-planned PTV dose was 
statistically equivalent to clinical dose and showed a significant improvement in CI (Table 8). Re-
plans also significantly decreased Dmean of both femoral heads by an average of 2.76 (left; p < 0.001) 
and 2.50 Gy (right; p < 0.001). A statistically significant increase (p = 0.007) in re-planned right 
femoral head Dmax was observed. However, D2 serves as a more stable surrogate for maximum dose 
since Dmax represents a point dose that is susceptible to interpolation errors, especially in large dose 
gradients. Compared with the clinical plans, the re-planned D2 values were 0.91(p = 0.02) and 0.56 
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Gy (p = 0.16) lower for the left and right femoral heads respectively. Lastly, the mean dose to the 
penile bulb decreased by an average of 4.0 Gy (p < 0.001) in the re-plans. 
 
Figure 10: Average PTV and secondary OAR DVHs of the 31 re-planned patients comparing the 
clinical plans (solid lines) and re-plans (dashed lines). Note the penile bulb was not segmented in 3 
of the 31 patients. 
The average bladder and rectum DVHs from the re-plans and the clinical plans are shown in 
Figure 11. The re-planned bladder and rectum dose was statistically lower (p < 0.001) than the 
clinical plan dose for each dose-volume observed (Table 9). This resulted in an average decrease in 
mean dose of 7.81 (p < 0.001) and 9.41 Gy (p < 0.001) for the bladder and rectum respectively. 
Statistical results from comparing KBP model and re-planned bladder and rectum dose are 
shown in Table 10. Overall, seven of the ten predicted bladder and rectum dose-volumes were 
statistically equivalent to the attained re-planned values. The re-planned D10 dose-volumes of the 
bladder and rectum were on average 1.06 (p = 0.03) and 0.82 Gy (p = 0.04) higher respectively than 
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the KBP model predicted values. Additionally, the KBP model predicted D65 of the rectum were on 
average 1.74 Gy lower (p = 0.03) than the re-planned values. 
Table 8: Statistical results of the dose comparison between the clinical plans and re-plans for the 
PTV and secondary OARs. While the PTV and femoral head dose metrics were averaged over the 
31 patients, the penile bulb was averaged over the 28 patients in which it was segmented. 
Dose Metric Mean Re-plan – Clinical  Wilcoxon p-value 
PTV 
D2 (cGy) 8.8 0.62 
D50 (cGy) -0.4 0.98 
D98 (cGy) 21.9 0.37 
Dmin (cGy) -160.1 0.08 
Dmean (cGy) 0.6 0.95 
Dmax (cGy) 20.7 0.43 
V95 (%) 0.06 0.89 
V98 (%) 0.07 0.98 
V100 (%) -0.2 0.22 
V107 (%) -0.4 0.80 
HI -0.002 0.84 
CI -0.07 0.03* 
Left Femoral Head 
D2 (cGy) -91.2 0.02* 
Dmax (cGy) 80.8 0.11 
Dmean (cGy) -275.7 < 0.001* 
Right Femoral Head 
D2 (cGy) -55.6 0.16 
Dmax (cGy) 127.0 0.007* 
Dmean (cGy) -249.7 < 0.001* 
Penile Bulb 
Dmean (cGy) -404.9 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
3.3 DISCUSSION 
This study showed the KBP models utilizing either plan database predicted a significant 
improvement in both bladder and rectum dose compared with clinical plans. Concretely, the two 
KBP models predicted that more than 7 and 8 Gy dose decreases to the bladder and rectum 
respectively were possible. These observed improvements are consistent with previous results from 
similar KBP models for prostate cancer.40,68,74 The large dose reductions again reveal the presence of 
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Figure 11: Average DVHs over the 31 patients of the bladder and rectum for the clinical plans (solid 
lines) and re-plans (dashed lines). 
sub-optimal clinical plans, resulting from the inconsistent nature of current inverse planning 
processes. This emphasizes the need for planning quality control methods, such as KBP, in clinical 
workflows to consistently achieve the best treatment plans for each patient.  
When comparing differences between the two individual KBP methods, the MCOD model 
predicted significantly lower bladder dose-volumes than the CPD model. Averaged over the five 
bladder dose-volumes, the MCOD KBP model predicted dose 3.75 Gy less than the corresponding 
CPD KBP model. While the MCOD KBP model did not predict statistically lower dose-volumes for 
every rectum dose-volume observed, it predicted an average of 1.04 Gy lower rectum dose than the 
CPD KBP model for D50 and D65. Also, the results from the re-planning study affirm the 
achievability of these lower MCOD KBP dose-volume predictions. Therefore, this study shows how 
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a KBP model using a database of Pareto plans can lead to a higher degree of plan quality than a 
clinical plan database overall. 
This study supplements and advances the implications from Wang et al.’s validation of the 
OVH KBP model using an in-house MCO protocol with consistent prostate planning priorities.69 
They realized the shortfalls of evaluating the accuracy of planning quality assurance methods by 
comparing predictions with the potentially sub-optimal clinical plans. However, their set of Pareto 
plans was generated based on a hierarchical wish-list that prioritized certain OAR sparing over 
others, which they suspect may have led to an underestimation of bladder dose. Our study used a 
uniformly weighted MCO planning protocol within a commercial TPS to generate consistent Pareto 
plans. This study also quantified the degree to which an OVH KBP method can be improved by 
using a Pareto plan database compared to using a clinical, inversely optimized plan database. 
Further, these more optimal dose-volume predictions obtained through the MCOD KBP model 
were shown to be achievable through traditional inverse optimization.  
Table 9: Average differences in re-planned and clinical dose values over the 31 patients with 
Wilcoxon test results for the primary OARs. 
  Wilcoxon p-value 
Dose Metric 
Mean 
Re-plan – Clinical 
(cGy) 
Re-plan 
vs. 
Clinical 
Bladder 
D10 -584 < 0.001* 
D30 -1184 < 0.001* 
D50 -939 < 0.001* 
D65 -833 < 0.001* 
D80 -703 < 0.001* 
Dmean -781 < 0.001* 
Rectum 
D10 -345 < 0.001* 
D30 -1223 < 0.001* 
D50 -1543 < 0.001* 
D65 -1366 < 0.001* 
D80 -857 < 0.001* 
Dmean -941 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
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This suggests that institutions without MCO capabilities could leverage external Pareto plan data in 
an existing KBP model to achieve treatment plans more optimal than those predicted by historical 
clinical plans. In other words, a MCO-driven KBP model can be made portable and used to achieve 
MCO-type plans through traditional inverse optimization. 
Table 10: Dosimetric and statistical results for evaluating prediction performance and achievability. 
   Wilcoxon p-value 
Dose Metric 
Number  
Of 
Predictions 
Mean 
Re-plan – Prediction 
(cGy) 
Re-plan 
vs. 
Prediction 
Bladder    
D10 31 106 0.03* 
D30 27 -5 0.77 
D50 18 -12 0.65 
D65 13 -165 0.13 
D80 9 17 0.95 
Rectum    
D10 31 82 0.04* 
D30 31 -174 0.23 
D50 30 -13 0.52 
D65 23 -174 0.03* 
D80 13 -151 0.12 
*Indicates a statistically significant result of p < 0.05 
Our study shows that predictions from an OVH KBP model can be improved through the 
use of a consistently generated Pareto plan database without compromising prediction achievability 
or accuracy. However, we did not find the MCOD model to be more optimal in each analyzed dose-
volume, namely the two high-dose rectum volumes. It is possible the CPD model predicted lower 
doses for rectum D10 and D30 due to varying clinical priorities placed on the rectum. Conversely, it 
may be a result of the fixed planning priorities imposed on the Pareto plans of the MCOD. The 
minimum dose constraint to the target used in the MCO planning protocol (Table 2) likely serves to 
increase the dose to rectum volumes close to the target. This could suggest a refinement of the 
Pareto plan generation, such as additional trade-off objectives emphasizing high-dose rectal 
volumes, could further improve these rectum dose-volume predictions.  
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Planning efficiency was not accounted for or analyzed in the present study as the main 
purpose was to investigate the effects of utilizing a dose database of improved quality and 
consistency on KBP performance. The present workflow was also not optimized for efficiency. 
However, given the previous findings of KBP methods improving planning efficiency, it would 
seem reasonable that incorporating another dose database into an existing KBP protocol would not 
compromise the method from an efficiency standpoint. However, an examination on treatment 
planning efficiency of a KBP method with a separately constructed plan database is needed to verify 
this claim. 
In order to further improve KBP model performance, a logical progression of the OVH-
driven KBP dose-volume prediction method would be the development of an OVH-based KBP 
prediction tool for equivalent uniform dose (EUD) planning objectives. The accurate prediction of 
an optimally achievable EUD objective could further improve patient-specific KBP plan quality. 
Additionally, as with all KBP planning methods, the plan databases may be continuously updated to 
include high-quality plans generated via the KBP method.  
3.4 CONCLUSIONS 
The results from this study showed the dosimetric advantages of an OVH-driven KBP 
model using either a clinical plan database or a Pareto plan database. This study also demonstrated 
that a Pareto plan database can produce lower dose-volume KBP predictions than a clinical plan 
database without jeopardizing achievability. Five out of five bladder and two out of five rectum 
dose-volume predictions were found to be more optimal using the MCOD compared with the 
conventional CPD. Overall, dose-volume predictions were shown to be achievable regardless of 
plan database origin, with average differences of no more than 1.74 Gy with the re-planned bladder 
and rectum dose-volumes. Further, these results indicate the possibility of achieving MCO-type 
plans through inverse planning optimization.
 46 
CHAPTER 4. CONCLUSIONS 
4.1 SUMMARY OF FINDINGS 
The main goal of this study was to evaluate the extent to which the performance of an 
OVH-driven KBP model for predicting dose-volumes is affected by plan quality deficiencies and 
variations in the plan database. Sub-optimal and inconsistent treatment plans in a large database of 
prostate patients due to inter-planner subjectivity were controlled for by applying a uniform MCO 
planning protocol to create a balanced Pareto optimal plan for each database patient. KBP model 
dose-volume predictions generated from the clinical, manually-optimized plan data (i.e. the CPD) 
were compared to those derived from the database of Pareto plans (i.e. the MCOD). Achievability 
of those dose-volume predictions were verified by re-planning a subset of randomly selected patients 
with the KBP model predictions as planning goals. 
When establishing the distance-to-dose relationship for querying new patients against the 
database for patients with similar anatomies (see Chapter 2), we observed a sizable variation in dose 
a specific fractional OAR volume received (i.e. a DVH point) at a given distance away from the PTV 
surface (i.e. a OVH point). These large spreads in the DVH-OVH correlations for a fractional OAR 
volume could lead to less accurate and namely less achievable dose-volumes in an OVH-driven KBP 
model. Therefore, we investigated the influence of second-order factors on this distance-to-dose 
correlation variation while again accounting for sub-optimal planning due to inter-planner bias. We 
found the in-field OAR volume correlated strongest with MCOD dose for each observed dose-
volume of both the bladder and rectum. Other second-order variables, such as prescription dose and 
bladder and rectum fill volumes, did not correlate with OAR dose. The derivative of the OVH and 
PTV volume moderately correlated with OAR dose. Recalculating the OVH to only consider OAR 
volume within the treatment fields resulted in an overall strengthening in the distance-to-dose 
correlation of the bladder and rectum. This in-field OVH removed data points that would likely 
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result in unachievably low dose-volume predictions and was selected to be the feature querying 
metric for the KBP model used in this study. 
Chapter 3 detailed the results from comparing an OVH-based KBP model using a clinical 
plan database (CPD) with one using a Pareto plan database (MCOD). The MCOD KBP model 
predicted statistically lower dose than the CPD KBP model for all five bladder dose-volumes and 
two of five rectum dose-volumes observed. A re-planning study confirmed the achievability of these 
KBP predictions while maintaining statistically similar PTV and secondary OAR dose as the original 
clinical plans. Therefore, a database of uniform Pareto plans can produce more optimal dose-volume 
predictions that lead to improved plan quality compared with a conventional clinical plan database. 
The hypothesis of this study was that OVH-driven KBP bladder and rectum dose-volume 
predictions derived from the MCOD database of Pareto plans versus those derived from the CPD 
database of inversely optimized clinical plans would result in plans with statistically improved (p < 
0.017) sparing of the bladder and rectum, while also maintaining statistically equivalent PTV and 
secondary OAR dose. To this end, the results fully support this hypothesis for the bladder as the 
MCOD model produced achievable and statistically lower predictions than the CPD model for each 
dose-volume considered. As for rectum, however, MCOD model predictions were statistically lower 
than those from the CPD model for only D50 and D65 dose-volumes. Nonetheless, the MCOD KBP 
model led to improved and achievable overall bladder and rectum dose sparing, while still 
maintaining statistically similar PTV and secondary OAR dose. 
4.2 LIMITATIONS 
One limitation of this work is the size of the patient database. Naturally, the larger the 
patient database, the more robust a KBP method should be. Boutilier et al.’s study found that more 
than 200 samples gives the most consistent OVH-driven KBP model dose-volume predictions.74 
However, they also show a database size of 100 patients still results in a similarly consistent and 
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accurate KBP model compared with a 200 patient database. Specifically, a KBP model with a sample 
size of 100 patients produced a similar number of “over-predictions” (i.e. predictions where a 
dosimetric value was worse than the clinical value) for bladder and rectum dose-volumes compared 
to a model with 200 patients. Given time constraints, the working sample size of 124 was 
predetermined to yield adequate model performance and statistical power for the purposes of this 
project. 
This study also restricts database patients to those with only one prescribed PTV. This 
aspect has been discussed by previous groups dealing distance-to-dose KBP methods similar to the 
one used in this study.44,69 For cases that require more than one segmented PTV, such as 
simultaneous integrated boosts (SIB), an OAR will have separate OVHs for each defined PTV with 
likely differing prescription doses. However, the model in this study could theoretically be adapted 
to predict dose-volumes for SIB treatments by compiling a database of previous SIB patients. Wang 
et al. provides an example of such a formalism.69 This logic extends to other, more complex 
treatment sites as well (e.g. head and neck), although model testing would still be needed to confirm 
the method’s clinical viability. 
There was also not a comprehensive analysis of how the in-field OVH KBP predictions 
compared to the nominal OVH KBP predictions in this study. Despite being out of the scope of 
this thesis, results from qualitative inspection comparing the two OVH methods in the re-planning 
study can be found in the supplemental material (see Appendix F). A preliminary statistical analysis 
between the achieved re-planned and the predicted nominal OVH dose-volumes can also be found 
in Appendix G. Additionally, Petit et al. performed a similar comparison study with IMRT pancreatic 
adenocarcinoma patients and they found the in-field OVH produced more accurate and achievable 
liver dose-volume predictions than the standard OVH. These findings suggest a similar discovery is 
likely with the VMAT prostate patients in this study. 
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Since in-field OVH-driven KBP dose-volume predictions were not made for patients with 
less than the given in-field OAR volume threshold, there were missing statistical data when 
evaluating the prediction achievability in the re-planning study. The signed-rank Wilcoxon statistical 
function used for these comparisons cautions the inability to perform a normal approximation with 
a sample size of less than 10. This warning only arises for D80 of the bladder, which had only 9 KBP 
predictions. Although these missing data do decrease the statistical power of the Wilcoxon test, 31 
re-planned patients is a sufficient overall sample size to confidently interpret the results. Further, a 
pilot study determined that 30 or more patients was an adequate sample size in order to detect a 
significant difference of about 2 Gy with 80% power.  
Another limitation of this study is the lack of biological plan quality metrics (e.g. target 
control probability, normal tissue complication probability, secondary cancer complication 
probability etc.) that could be used to evaluate potential outcome differences in two treatment plans. 
The purpose of this study was to assess dosimetric differences between plans only. Although outside 
the scope of this project, investigation into the differences in biology-based metrics between both 
sets of KBP predictions and results from the re-planning study could supplement the dosimetric 
findings in this study. 
4.3 FUTURE WORK 
The next logical and immediate step for this project would be to further identify outliers 
present in the patient database. This was addressed primarily through the in-field OVH in the 
present study. However, one could imagine taking other factors that were found to moderately 
influence the distance-to-dose relationship (e.g. dOVH and PTV volume) and incorporating them 
into the dose-volume prediction through multiple linear regression, for example. 
Another direction that one could take is the investigation of a more optimal MCO planning 
protocol than the one used in this work. While the MCO balance plan yields a plan independent of 
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inter-planner variations, there likely exist Pareto plans that are more optimal for a specific OAR. The 
MCO planning protocol applied to each database patient in this study produced uniformly 
consistent Pareto plans, regardless of relative OAR priorities. This is in contrast to the manually 
optimized clinical plans, where physician preference can result in plans where one particular OAR 
was emphasized at the expense of the other. The independence of OAR sparing priorities in the 
MCO planning protocol may explain, at least partially, why the CPD model predicted statistically 
lower D10 and D30 rectum dose-volumes. Regardless, a custom optimization protocol could be 
developed to search each patient’s Pareto surface based on certain planning priorities, which could 
result in even more optimal KBP dose-predictions, albeit at the expense of increased computational 
overhead.  
As mentioned in Chapter 1.1.3, KBP methods can be applied at multiple levels of the 
treatment planning process. The KBP method developed in this study can be adapted for pre- or 
post-planning quality assurance. Therefore, clinically implementing this KBP method for either pre-
planning dose-volume predictions or flagging sub-optimal plans post-planning is a natural 
progression from this work. Further, the extension of this KBP structure to other treatment sites 
should be investigated before considering clinical implementation. 
As part of the clinical validation of this KBP model, a study would need to be done verifying 
the deliverability of the KBP-assisted plans (e.g. the re-plans in this study). While not studied in 
detail, a cursory inspection of the re-plans indicated a sizeable increase in the MUs required relative 
to the original clinical plans. The amount of required MUs is a general, although not exact, indicator 
of plan complexity as defined by the modulation complexity score.75,76 The increased complexity of 
the re-plans trying to achieve the KBP model dose-volume predictions may affect the plans ability to 
pass quality assurance tests. As the re-plans were not planned under the exact same conditions (from 
a technical perspective e.g. different TPS, machine, etc.) as the clinical plans, a quality assurance 
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assessment of the re-plans is needed to confirm the clinical viability of the resulting plans. This, 
however, was outside the purpose and scope of the current project.  
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APPENDIX A. EXTRANEOUS MATERIALS AND METHODS 
A.1 PATIENT ANONYMIZATION 
The process of patient data anonymization is an important step in performing treatment 
planning research. This task was laborious in this study due to the various locations patient data can 
reside within Mary Bird Perkins Cancer Center (MBPCC) depending on the treatment status of a 
particular patient. In other words, a patient could be in the middle of his or her treatment or fully 
completed, meaning the DICOM data could be active or archived respectively. For the purposes of 
this project, active patient DICOM data within MBPCC can most easily be obtained from within 
Mobius3D (Mobius Medical Systems LP, Houston, TX), a software application for quality assurance 
and treatment plan verification that also features a DICOM anonymization tool. On the other hand, 
archived patient data housed in MBPCC’s radiation oncology information system MOSAIQ (Elekta, 
Stockholm, Sweden) must be restored before anonymization. 
At MBPCC, the DICOM data is transferred to Mobius3D for a plan check once a plan has 
been completed and physician-approved in Pinnacle. This patient data and the plan report remain in 
the plan check list for a given amount of time before the data is archived to MOSAIQ. From this 
list, a patient’s anonymized DICOM data can be downloaded using the Mobius3D anonymization 
feature. Therefore, this plan check list was first searched for suitable database patients. If a patient 
met the previously defined selection criteria, the anonymized DICOM data was downloaded before 
being transferred to and imported into RayStation.  
After the patient search through the Mobius3D plan check list was exhausted, archived 
database candidates were searched using MOSAIQ. A report categorized by primary diagnosis was 
run in MOSAIQ in order to selectively search the entire MOSAIQ database for a cohort of possible 
candidates. The report was configured to return a list of all patients treated within a specified time 
frame in the MBPCC system with a primary cancer diagnosis of “Prostate.” Patients with statuses 
 59 
other than “New” were reviewed for database selection (i.e. only patients with clinically-approved 
treatment plans). The plan summary of each potential database patient was examined to determine 
whether selection criteria were met. The DICOM data of patients meeting the selection criteria 
needed to be restored in the TPS. 
Patient data can be backed up to electronic media in Pinnacle. Patients at MBPCC are 
archived to the MOSAIQ Data Director (MDD), an integrated image and data archiving software 
system. When patient data is ready to be archived, all image sets and DICOM-RT files associated 
with that patient are backed up to MDD. Specifically, all archived image sets are listed along with a 
Pinnacle-specific .tar file that contains header information needed to restore the patient DICOM 
data to Pinnacle. In order to restore an archived database patient to Pinnacle, the original primary 
image set and the corresponding .tar file need to be downloaded and pushed to the Pinnacle server. 
Once the .tar file was transferred to the Pinnacle server, the patient was restored via the 
header file contained in the tarball. The primary CT set transferred from MOSAIQ was then 
imported into that patient. However, for the DICOM image set to be exported to Mobius3D with 
the same instance as the other DICOM-RT files (i.e. so that all DICOM files can be properly 
imported into RayStation), the restored DICOM image set must be assigned as the primary image 
set of the patient. This was done by copying the restored plan to the imported DICOM image set, 
which produced an identical plan to the restored plan except with no dose. The dose was 
recomputed for both VMAT beams and the patient data was ready to be exported to Mobius3D for 
anonymization. 
All patient data was anonymized in Mobius3D and imported into RayStation in this fashion 
until the target number of database patients was achieved. In total, 124 database patients were 
imported into RayStation for this study. 
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A.2 DATABASE STANDARDIZATION AND PREPARATION 
There are numerous benefits to standardizing nomenclature for body and organ structures, 
DVH metrics, toxicity, units etc. in radiation therapy. For example, standardizing RT nomenclature 
can enable easy pooling of data across institutions as well as minimize systematic communication 
errors within a single institution. With the growing prevalence of large data studies and clinical trials, 
the American Association of Physicists in Medicine recently approved the formation of Task Group 
No. 263 for Standardizing Nomenclature for Radiation Therapy. For this study, the nomenclature 
standardization of select patient data objects was necessary for scripting automation and analysis 
purposes. 
Each anonymized patient imported into RayStation underwent a series of modifications in 
order to standardize each patient for future use, including OVH computations and DVH data 
extraction. First, the Tissue Name under the regions of interest (ROI) properties for each specified 
ROI was designated according to the list in Table 11, which were largely adapted from the RTOG 
0126 protocol.77 These labels would serve as object identifiers in future automation routines, as the 
names of the structures created by original planners were not uniform. Additionally, each External 
ROI was modified in RayStation to encompass the entire patient surface included in the CT set.  
Each patient image set was required to have an assigned Imaging System. Therefore, each 
database patient’s Imaging System was set to the Generic CT table used to commission the TPS. 
Then, each imported plan was copied and renamed “MCO_pw,” which would serve as the plan file 
where the MCOD plan would be generated for each database patient. Plan properties were set to 
uniquely differentiate the MCO plan from the clinical plan and each MCOD plan was set to the 
same treatment machine. From there, MCO plan development commenced. 
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Table 11: List of structures used in this study and their assigned standardized Tissue Name labels. 
The in-field structures were created for computing the in-field OVH in this study as will be 
discussed in A.3. 
Patient Structure Standardized Tissue Name 
PTV PTV 
Bladder BLADDER 
Rectum RECTUM 
Left Femoral Head FEMUR_LT 
Right Femoral Head FEMUR_RT 
Penile Bulb PENILE_BULB 
External EXTERNAL 
In-field Bladder BLADDER_IN 
In-field Rectum RECTUM_IN 
A.3 NOMINAL AND IN-FIELD OVH COMPUTATIONS 
An IronPython script was written to automate the OVH computation process from within 
RayStation. The script was designed to loop through a list of patients in the RayStation database and 
compute the OVHs for the bladder and rectum of each patient. The script takes a list of unique 
patient IDs as input and outputs the bladder and rectum OVH data in a patient-specific text files. 
The script algorithm takes advantage of the built-in ROI tools of RayStation by first 
selecting and copying the PTV ROI in the plan, which serves as the working copy of the original 
PTV contour. Then, ROI algebra is performed to find the intersections between the bladder and 
PTV ROIs and between the rectum and PTV ROIs, which represent the bladder and rectum volume 
overlapping with the PTV respectively. Then those overlap volumes are divided by the total volumes 
of the bladder and rectum ROIs respectively, yielding the bladder and rectum OVH values at a 0 cm 
expansion distance. Three data items are then written to a patient-specific text file: the current OVH 
expansion/contraction distance (cm), the bladder OVH value, and the rectum OVH value. The 
newly created ROIs required for this process are deleted before moving to the next OVH data point 
to prevent memory leaks. Then a new copy of the PTV is created with a surface uniformly expanded 
by 1 mm and the process continues as just described. This entire process continues until both the 
bladder and rectum OVH values are above 85% volume.  
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Once the OVH expansions are completed for both bladder and rectum ROIs, the same 
iterations described previously are executed, except the PTV ROI surface is uniformly contracted in 
1 mm steps. This process continues until both the bladder and rectum OVH values are 0%. At this 
point, the text file contains both bladder and rectum OVHs from 0% to at least 85% volumes. This 
script prevented the computation from continuing until 100% volume overlap due to time efficiency 
and the specific needs of this project (i.e. largest value needed was 80% to predict the D80 dose-
volume). The PTV ROI copying process becomes prohibitively time-consuming the larger the 
expansion value presumably due to the memory requirements from the large number of structure 
voxels.  
This script would then loop to the next database patient in the input list and begin the OVH 
computation for that patient. The script would continue in this manner until each patient in the list 
was complete.  
In order to compute the in-field OVHs for the bladder and rectum ROIs, in-field ROIs for 
each structure needed to be generated. A separate IronPython script was written to consistently 
automate this process like the OVH computation script. In-field volume was defined as ROI volume 
within the transverse planes located 6 mm (to approximate beam penumbra at depth) superior and 
inferior to the most superior and inferior aspects of the PTV, respectively. Therefore, to create these 
in-field ROIs, a copy of the PTV ROI was expanded by 6 mm in the superior and inferior directions 
and 15 cm in the left, right, anterior, and superior directions. Then the intersections between the 
bladder and new PTV ROI and between the rectum and new PTV ROI were created to represent 
the in-field bladder and rectum ROIs. An example of the ROIs generated from this script is shown 
in Figure 12. This process was repeated for each database patient. 
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Figure 12: Sagittal CT slice of a database patient showing the estimation of the treatment fields. The 
horizontal lines are part of the ROI created from the original PTV contour to represent the 
treatment fields. Given Tissue Names are listed with their corresponding ROIs, with the in-field 
OAR portions indicated by “_IN.” Note the femoral heads are not visible and are located to the left 
and right of the shown CT slice. 
 
The OVH computation script was modified and adapted to compute the in-field OVHs for 
the bladder and rectum ROIs in each patient. The major adjustment was to select the 
“BLADDER_IN” and “RECTUM_IN” planning objects instead of the nominal objects at the 
beginning of the script. The in-field OVH computation process was identical to the standard OVH 
script, except the in-field OVH script continued expanding until 100% of the in-field bladder and 
rectum ROIs were overlapped by the expanded PTV. Again, patient-specific text files were written 
to contain the in-field OVH data for both the in-field bladder and rectum ROIs.  
A.4 STATISTICAL ANALYSIS OF CLINICAL AND PREDICTED DOSE-VOLUMES 
The Wilcoxon signed-rank test used in this study is a non-parametric test for testing the null 
hypothesis that two related paired samples come from the same distribution. It is the non-parametric 
version of the student t-test. Deciding to use this particular test was based on results from testing 
data distribution assumptions. The use of parametric statistical tests assumes the data are normally 
distributed and the variances of the compared samples are similar. Therefore, prior to the individual 
statistical comparisons performed on the dose-volume distributions of the clinical, CPD, and 
Estimation 
of  
Treatment 
Fields
RECTUM_IN
BLADDER_IN
PTV
RECTUM
BLADDERRECTUM
PENILE_BULB
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MCOD data (detailed in Chapter 3.1), normality and omnibus statistical tests were performed on the 
three distributions of data. This statistical analysis process was adapted and based on the methods 
described by Chaikh et al.78 Also, all statistical tests were performed using the statistical functions 
module in SciPy (scipy.stats), an open-source Python library for scientific computing. 
Out of the numerous possible statistical tests designed to assess normality, the Shapiro-Wilk 
test was used in this work (scipy.stats.shapiro). The Shapiro-Wilk test tests the null hypothesis that 
the data was drawn from a normal distribution, where a p-value of less than 0.05 indicates a 
significant difference between the test data and a normal distribution (i.e. the data is likely non-
normal). Normality tests are often complemented by measuring the skewness and the kurtosis of the 
data distributions. The skewness describes the symmetry of the data while kurtosis quantifies the 
spread or peak sharpness of the distribution. A statistical test based on D’Agostino and Pearson’s 
test was used in this study to further evaluate normality of the distributions of data 
(scipy.stats.normaltest). This test combines skew and kurtosis tests to produce an omnibus test of 
normality where again, a p-value of less than 0.05 indicates a significant difference (i.e. the data is 
likely non-normal).  
These normality statistical tests were performed on each of the three distributions of data: 
the original, clinical data, the CPD-derived KBP predictions, and the MCOD-derived KBP 
predictions. These tests yielded p-values for each of the five bladder and five rectum dose-volumes 
observed in this study and can be seen in Table 12. These results indicated that a large majority of 
the data sets tested were likely non-normal distributions. To further support this interpretation, each 
data set was visually inspected via histograms and compared with fitted normal distributions. Two 
representative examples can be seen in Figure 13. Boxplots of the data may also be used as a visual 
tool when determining normality. The data visualization confirmed the normality tests and the 
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decision was made to proceed with non-parametric statistical tests. Uniform variance was not tested 
in this study since a repeated measures design was used. 
Table 12: Normality statistical test p-values for the three distributions of data. A statistically 
significant result may be interpreted as the given data likely representing a non-normal distribution. 
Dose-Volume N† Clinical Data CPD Model MCOD Model Shapiro Normal Shapiro Normal Shapiro Normal 
Bladder        
D10 123 < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* 
D30 107 0.01* 0.046* 0.001* 0.002 < 0.001* < 0.001* 
D50 75 0.03* 0.10 < 0.001* <0.001* < 0.001* 0.006* 
D65 51 0.03* 0.03* < 0.001* <0.001* < 0.001* < 0.001* 
D80 34 0.08 0.03* < 0.001* <0.001* < 0.001* < 0.001* 
Rectum        
D10 123 < 0.001* < 0.001* < 0.001* 0.43 < 0.001* < 0.001* 
D30 123 0.25 0.72 < 0.001* < 0.001* < 0.001* < 0.001* 
D50 116 0.86 0.77 < 0.001* 0.005* < 0.001* < 0.001* 
D65 89 0.63 0.76 < 0.001* < 0.001* < 0.001* < 0.001* 
D80 48 0.31 0.28 < 0.001* 0.005* < 0.001* < 0.001* 
*Indicates a statistically significant result of p < 0.05 
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible 
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dose-
volume 
After carrying out the normality statistical test, an omnibus test was performed. Conducting 
an omnibus test is typically the first step when performing more than one statistical comparison. A 
total of three comparisons were made in this part of the study: Clinical vs. CPD, Clinical vs. MCOD, 
and CPD vs. MCOD distributions. The omnibus test checks whether there exists a difference 
between any of the datasets. In other words, it tests whether all datasets are statistically equivalent. If 
no statistically significant result is achieved, there is no need to continue to one-on-one comparisons 
between the individual datasets.  
This study used the Friedman test to conduct the omnibus test 
(scipy.stats.friedmanchisquare), which tests the null hypothesis that repeated samples of the same 
individuals have the same distribution. Therefore, a statistically significant result means it is likely a 
difference exists between the distributions tested. This test is the non-parametric equivalent of the 
repeated measures analysis of variance (ANOVA) test. The p-values resulting from the Friedman test  
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Figure 13: Representative examples of data visualization via density distribution histograms along 
with estimated normal curves, plotted using the mean and standard deviation of the data. (a) is an 
example of a distribution determined to likely be non-normal and (b) is an example of a distribution 
deemed to be normal. 
(a) 
(b) 
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are shown in Table 13. Each bladder and rectum dose-volume yielded a statistically significant result, 
indicating the need to perform one-on-one comparisons. This was accomplished via multiple 
Wilcoxon signed-rank tests, the results of which are detailed in Chapter 3.1.3. 
Table 13: Results from the omnibus test. Each dose-volume yielded statistically significant results, 
indicating a difference likely exists between the three distributions of data. 
Dose-Volume N† Friedman Test p-value 
Bladder   
D10 123 <0.001* 
D30 107 <0.001* 
D50 75 <0.001* 
D65 51 <0.001* 
D80 34 <0.001* 
Rectum   
D10 123 <0.001* 
D30 123 <0.001* 
D50 116 <0.001* 
D65 89 <0.001* 
D80 48 <0.001* 
*Indicates a statistically significant result of p < 0.05 
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible 
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dose-
volume
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APPENDIX B. CPD VERSUS MCOD NOMINAL DVH-OVH 
CORRELATIONS  
 
Figure 14: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 30% dose-volume of the bladder. 
 
Figure 15: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 50% dose-volume of the bladder. 
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Figure 16: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 65% dose-volume of the bladder. 
 
 
Figure 17: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 80% dose-volume of the bladder. 
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Figure 18: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 30% dose-volume of the rectum. 
 
 
Figure 19: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 50% dose-volume of the rectum. 
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Figure 20: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 65% dose-volume of the rectum. 
 
 
Figure 21: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD 
DVH data (squares) for the 80% dose-volume of the rectum. 
  
 72 
Table 14: Summary of the Pearson correlation coefficients for the distance-to-dose relationships 
formed with the CPD and MCOD dose data. The nominal OVH data was used for these 
correlations. The MCOD dose produced a stronger correlation with distance overall, most 
noticeably in the rectum. This is most likely due to the removal of the inter-planner subjectivity 
present in the CPD dose data. 
Dose-Volume 
DVH-OVH R 
CPD MCOD 
Bladder   
D30 -0.91 -0.92 
D50 -0.84 -0.83 
D65 -0.73 -0.74 
D80 -0.65 -0.66 
Mean -0.78 -0.79 
Rectum   
D30 -0.75 -0.94 
D50 -0.67 -0.86 
D65 -0.68 -0.78 
D80 -0.65 -0.70 
Mean -0.69 -0.82 
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APPENDIX C. COLOR BAR CORRELATION PLOTS OF SECOND-
ORDER FACTORS 
 
Figure 22: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the derivative of the OVH. 
 
Figure 23: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the derivative of the OVH. 
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Figure 24: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the 
color-mapped variable is the derivative of the OVH. 
 
 
Figure 25: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the derivative of the OVH. 
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Figure 26: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the derivative of the OVH. 
 
 
Figure 27: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the derivative of the OVH. 
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Figure 28: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the 
color-mapped variable is the derivative of the OVH. 
 
 
Figure 29: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the derivative of the OVH. 
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Figure 30: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the prescription dose. 
 
 
Figure 31: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the prescription dose. 
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Figure 32: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the 
color-mapped variable is the prescription dose. 
 
 
Figure 33: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the prescription dose. 
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Figure 34: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the prescription dose. 
 
 
Figure 35: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the prescription dose. 
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Figure 36: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the 
color-mapped variable is the prescription dose. 
 
 
Figure 37: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the prescription dose. 
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Figure 38: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the PTV volume. 
 
 
Figure 39: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the PTV volume. 
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Figure 40: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the PTV volume. 
 
 
Figure 41: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the PTV volume. 
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Figure 42: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the PTV volume. 
 
 
Figure 43: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the PTV volume. 
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Figure 44: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the bladder volume. 
 
 
Figure 45: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the bladder volume. 
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Figure 46: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the 
color-mapped variable is the bladder volume. 
 
 
Figure 47: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the bladder volume. 
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Figure 48: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the bladder volume. 
 
 
Figure 49: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the bladder volume. 
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Figure 50: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the 
color-mapped variable is the bladder volume. 
 
 
Figure 51: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the bladder volume. 
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Figure 52: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the rectum volume. 
 
 
Figure 53: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the rectum volume. 
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Figure 54: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the 
color-mapped variable is the rectum volume. 
 
 
Figure 55: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the rectum volume. 
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Figure 56: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the rectum volume. 
 
 
Figure 57: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the rectum volume. 
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Figure 58: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the 
color-mapped variable is the rectum volume. 
 
 
Figure 59: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the rectum volume. 
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Figure 60: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the 
color-mapped variable is the in-field OAR volume. 
 
 
Figure 61: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the 
color-mapped variable is the in-field OAR volume. 
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Figure 62: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the 
color-mapped variable is the in-field OAR volume. 
 
 
Figure 63: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the 
color-mapped variable is the in-field OAR volume. 
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Figure 64: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the 
color-mapped variable is the in-field OAR volume. 
 
 
Figure 65: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the 
color-mapped variable is the in-field OAR volume. 
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APPENDIX D. NOMINAL VERSUS IN-FIELD OVH DISTANCE-TO-
DOSE CORRELATIONS 
 
Figure 66: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data 
(diamonds) for the 30% dose-volume of the bladder.  
 
Figure 67: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data 
(diamonds) for the 50% dose-volume of the bladder. 
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Figure 68: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data 
(diamonds) for the 30% dose-volume of the rectum. 
 
 
Figure 69: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data 
(diamonds) for the 50% dose-volume of the rectum. 
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APPENDIX E. PLAN DATABASE DOSIMETRIC COMPARISON 
Table 15: Statistical results of the dose comparison between the two plan databases for the PTV and 
secondary OARs. The mean differences between the MCOD and CPD dose metrics were averaged 
over the 124 database patients. 
Dose Metric Mean MCOD – CPD  Wilcoxon p-value 
PTV 
D2 (cGy) -140.8 < 0.001* 
D50 (cGy) -124.6 < 0.001* 
D98 (cGy) 133.4 < 0.001* 
Dmin (cGy) 650.5 < 0.001* 
Dmean (cGy) -101.5 < 0.001* 
Dmax (cGy) -62.3 < 0.001* 
V95 (%) 0.56 < 0.001* 
V98 (%) 1.40 < 0.001* 
V100 (%) -6.05 < 0.001* 
V107 (%) -0.23 < 0.001* 
HI -0.03 < 0.001* 
CI -0.13 < 0.001* 
Left Femoral Head 
D2 (cGy) -2506 < 0.001* 
Dmax (cGy) -2077 < 0.001* 
Dmean (cGy) -2189 < 0.001* 
Right Femoral Head 
D2 (cGy) -2492 < 0.001* 
Dmax (cGy) -2058 < 0.001* 
Dmean (cGy) -2187 < 0.001* 
Penile Bulb 
Dmean (cGy) -994 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
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Table 16: Statistical results of the dose comparison between the two plan databases for the primary 
OARs. The mean differences between the MCOD and CPD dose metrics were averaged over the 
124 database patients. 
  Wilcoxon p-value 
Dose Metric 
Mean 
MCOD – CPD 
(cGy) 
Re-plan 
vs. 
Clinical 
Bladder 
D10 -542 < 0.001* 
D30 -879 < 0.001* 
D50 -643 < 0.001* 
D65 -520 < 0.001* 
D80 -473 < 0.001* 
Dmean -581 < 0.001* 
Rectum 
D10 -137 < 0.001* 
D30 -434 < 0.001* 
D50 -541 < 0.001* 
D65 -578 < 0.001* 
D80 -557 < 0.001* 
Dmean -435 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
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APPENDIX F. PATIENT-BY-PATIENT PREDICTION ACHIEVABILITY 
PLOTS 
 
Figure 70: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for bladder D10. 
 
 
Figure 71: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for bladder D30. 
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Figure 72: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for bladder D50. 
 
 
Figure 73: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for bladder D65. 
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Figure 74: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for bladder D80. 
 
 
Figure 75: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for rectum D10. 
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Figure 76: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for rectum D30. 
 
 
Figure 77: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for rectum D50. 
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Figure 78: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for rectum D65. 
 
 
Figure 79: Patient-by-patient data from re-planning study comparing the original, clinical value 
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and re-
planned value (circle) for rectum D80.
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APPENDIX G. PRELIMINARY ACHIEVABILITY RESULTS FOR 
NOMINAL VERSUS IN-FIELD OVH PREDICTIONS 
Table 17: Statistical results comparing predictions from KBP model using the in-field OVH versus 
the nominal OVH feature metric.  
   Wilcoxon p-value 
Dose Metric Predictions 
Mean 
In-field – Nominal 
OVH Prediction 
(cGy) 
In-field 
vs. 
Nominal OVH 
Bladder    
D10 31 -6.9 0.32 
D30 27 239.0 0.05* 
D50 18 97.6 0.25 
D65 13 776.1 0.003* 
D80 9 865.2 0.007* 
Rectum    
D10 31 0.6 0.16 
D30 31 33.1 0.14 
D50 30 315.4 < 0.001* 
D65 23 917.3 < 0.001* 
D80 13 1056.2 0.002* 
*Indicates a statistically significant result of p < 0.05 
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